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Abstract 
My general research direction is the interface between organic chemistry and 
biology. Interesting biological systems inspire target-oriented organic synthesis, new 
methodology development, and molecular design of novel materials. On the other hand, 
chemical synthesis prepares important biologically active compounds to be used in 
understanding involved mechanism and engineering biological systems. 
We designed and synthesized a series of peptide-acridine conjugates based on the 
modular design principle to target RNA structures. Some of the peptide-acridine 
conjugates have substantially improved RNA-binding affinity and specificity relative to 
the peptide alone. We also generated various high-affinity inhibitors of the tRNA 
synthetases—aminoacyl sulfamide to create synthetic blanks in our translation extracts.  
The gaps were filled with chemically aminoacylated orthogonal tRNAs.  This unnatural 
strategy enables peptides and proteins to be constructed containing a single novel residue 
at specific locations and will facilitate the mRNA display-based protein selection. To test 
the versatility of ribosome, we have constructed a series of puromycin analogs with 
natural and unnatural amino acids side chains and tested the effects of side chain 
characteristics of amino acid moiety on the activity of puromycin analogs. We found that 
amino acids of different stereo characteristics can be incorporated via puromycin route, 
and larger hydrophobic amino acids render higher potency. 
Overall, these efforts demonstrate the successful use of a combination of 
molecular design as an efficient and facile method for generating new solutions to 
biological problems. 
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Chapter 1 
Design of Acridine-N Peptide Conjugates with Enhanced 
Binding Affinity and Specificity to RNA Targets 
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Abstract 
Arginine-rich peptides and small-molecule intercalating agents provide mechanistically 
distinct molecular tools for RNA recognition.  Here, we have worked to combine these 
distinct binding modules in an effort to create conjugate ligands with enhanced affinity 
and specificity using the bacteriophage λ N peptide/boxB RNA interaction as a model 
system.  To do this, we designed and synthesized a series of peptide-acridine conjugates 
using portions of the N RNA-binding domain (11 and 22 residue peptide segments).  We 
then compared the binding affinities, specificities, salt dependences, and structural 
properties of the RNA-peptide and RNA-peptide-conjugate complexes using steady-state 
fluorescence, CD spectroscopy, NMR, and native gel mobility shift assays (GMSA).  
These analyses revealed that the full-length peptide-acridine conjugate had substantially 
improved RNA-binding affinity (~80-fold; Kd ~ 20 pM) and specificity (~25-fold) 
relative to the peptide alone.  This binding enhancement was unique to only full length 
conjugates tested, implying that the structural context of acridine presentation was 
critical.  In line with this view, the specificity enhancement we observe results because 
binding of the best conjugate to a noncognate P22 RNA hairpin showed only a modest 
(3-fold) binding enhancement.  Our work supports the idea that peptide- and 
intercalation-based binding can be combined to create a new class of high-affinity, high-
specificity RNA-binding ligands.   
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Introduction 
The design of proteins with the capacity to recognize nucleotide sequences with high 
affinity and specificity has been pursued extensively. The information gained from 
designing DNA binders include utilizing zinc finger proteins to target sites in the major 
groove1-3 and polyamides to target sites in the minor groove.4-6 The ability of RNA 
molecules to fold into complex and unique three dimensional shapes and their important 
roles in many biological processes have generated great interest in designing sequence or 
structure-specific RNA-binding molecules. Recent successes of sequence-specific RNA 
binding molecules, the expansion of structural databases for RNA and RNA/protein 
complexes, together with the development of new synthetic tools, have provided new 
opportunities for the design of peptide or small molecule RNA binders. One approach to 
enhance RNA binding is to combine different binding modes using potential interaction 
sites that coexist in a given RNA molecule. In principle, if two binding sites are in close 
proximity, a dimeric derivative ligand can bind simultaneously to the two sites, resulting 
in binding affinity greater than either module.7,8 This strategy was also demonstrated in 
our efforts to select peptide-drug conjugates as novel inhibitors of the penicillin binding 
protein.9 In vitro selection of peptide-drug conjugates resulted in a penicillin-peptide 
conjugate that at least 100-fold higher activity than the parent penicillin itself. In this 
chapter, we discuss the recent successful application of these principles to create novel 
RNA-binding peptides, with particular emphasis on the advances achieved using 
intercalating agent acridine.  
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Recent studies have shown that the tethering of multiple binding modules can 
enhance RNA-binding affinity and specificity. In particular, acridine derivatives have 
proved very useful as intercalating modules. In a recent report, a Tat-TAR binding 
inhibitor consisting of a substituted acridine and a polyamine moiety was demonstrated to 
inhibit Tat function.10 Their modular design principle of Tat function impairment was 
based on the ability of the aromatic moiety of acridine for stacking, and a polycationic 
anchor for contacts with the TAR RNA phosphate backbone. The two modules are linked 
by an aliphatic linker. Aside from the compound stacking between two bases, direct 
hydrogen-bond contacts with a GC base pair were also involved. 
In another study, a series of cationic small molecules were synthesized and their 
binding abilities to defined RNA duplexes with and without bulged bases were 
investigated.11 Complex stabilization and selectivity for an RNA duplex containing a 
single bulged base over a normal RNA duplex have been obtained with a ligand 
consisting of a chloroacridine moiety covalently attached to 2,6-diaminopurine through 
an aminoalkyl linker. It is believed that the chloroacridine moiety intercalates into the 
RNA duplex and the 2,6-diaminopurine interacts with the bulged base.  
Another example of this type of binding enhancement is illustrated by a neomycin-
acridine conjugate, synthesized by covalently linking neomycin B to 9-aminoacridine via 
a short spacer, as a potent inhibitor of Rev-RRE binding.12 Its affinity to the RRE is about 
50-fold higher than that of the parent neomycin B and approaches that of the Rev 
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peptide. These results demonstrate that the combination of different binding modes (e.g.,  
ionic and intercalation) within one ligand is a powerful approach for enhancing the RNA 
affinity of synthetic binders. 
Acridine conjugation has also been used in designing functional molecules. For 
example, attachment of an acridine moiety to a catalytic tripeptide produced an RNase 
mimic,13 and attachment to a nucleic base-linker construct endowed with abasic site 
recognition generated DNA cleavage function at apurinic sites.14 Acridine has also been 
used in conjunction with an oligonucleotide to facilitate site-selective RNA hydrolysis.15 
In this case, acridine was hypothesized to push the bulged base out of the helix and 
present a scission site. 
We reasoned that the same principles may also apply to the N peptide/boxB RNA 
complex system. Bacteriophage N proteins play an essential role in transcriptional 
antitermination, which are critical for phage development.16 The inhibition of 
transcription termination at intrinsic and Rho-dependent terminators by N protein 
depends on recognition of a cis-acting RNA-element called Nut (N utilization) on the 
nascent phage transcript. Together with four Escherichia coli host factors (NusA, NusB, 
NusG, and ribosomal protein S10), they form a ribonucleoprotein complex that converts 
the RNA polymerase into a termination-resistant form. 16,17 
The Nut site consists of a 5'-single-stranded RNA element (boxA) and a 3' hairpin 
(boxB).18,19  The boxB from lambda phage is a 15-mer RNA stem-loop hairpin 
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containing a purine-rich pentaloop (Figure 1).  The RNA-binding domain of N protein 
consists of an arginine-rich motif located at the NH2-terminus.20  The 22-residue short 
peptide recognizes the cognate boxB RNA with similar specificity and affinity as the 
intact N protein.21  Upon complex formation, four of the pentaloop nucleotides adopt a 
canonical GNRA tetraloop fold22 with the fourth adenine extruded; 23,24 the peptide forms 
a bent α helix and binds tightly to the major groove of the RNA. 23-25  
The RNA–protein interface of the N22/boxB complex is dominated by electrostatic 
interactions and hydrophobic contacts.23 The five arginines and two lysines of N22 create a 
positively charged surface on one face of the α-helix that interacts with the negatively 
charged phosphodiester backbone of the boxB RNA. Hydrophobic interactions are also 
important for boxB recognition. Ala-3 and Trp-18 are involved in crucial hydrophobic 
interactions. In addition, the roles of arginine and lysine residues are not restricted to 
ionic interactions, and some of the aliphatic portions of these side chains also contact the 
RNA bases or sugars. 
The N/boxB complex is an ideal system for testing binding enhancement by 
introducing a new binding mode, e.g., intercalation. In this chapter, we report our efforts 
using acridine-peptide conjugates to enhance N peptide binding affinity against boxB 
RNA targets and demonstrate the recent successful application of these principles to 
create novel RNA-binding peptides, with particular emphasis on the advances achieved 
using intercalating agent acridine. 
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Materials and Methods 
 
Synthesis of peptides and acridine-peptide conjugates.  
Crude peptides with or without linkers were constructed by automated solid phase 
peptide synthesis using Fmoc protected monomers (ABI) on an Applied Biosystems 
432A peptide synthesizer. A series of full length λ N22 and truncated λ N11 acridine-
peptide conjugates were manually synthesized on the resin using the chemistry outlined 
in Scheme 1. Two types of flexible linkers, a Gly-Gly linker 1 and an ethylene glycol 
linker 2, were used. Crude peptides and crude acridine-peptides conjugates were 
deprotected and cleaved from the resin and purified by reverse-phase HPLC on a C18 
column. The purity of the products was checked by analytical HPLC and their identity 
confirmed by MALDI−TOF mass spectrometry. Concentrations of peptide stocks were 
determined by UV absorption at 280 nm for free peptides containing either tryptophan or 
tyrosine, or at 412/434 nm for acridine-peptide conjugates using extinction coefficients 
(ε=1.32×104cm-1M-1 at 412 nm, and 1.12×104cm-1M-1 at 434 nm) determined for a water 
soluble acridine derivative 3-acridin-9-ylamino-propanol synthesized from 9-
chloroacridine and 3-amino-1-propanol as described. 12 
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Scheme 1. Synthesis and quantification of acridine-peptide conjugates. 
 
λmax (nm)              ε (cm-1M-1) 
220                          2.84x104 
266                          6.99x104 
412                          1.32x104 
434                          1.12x104 
  
9
Synthesis of 2AP-labeled RNA oligomers.  
Crude RNA oligomers with fluorescent 2- aminopurine (2AP) label substituted for 
adenine at the 2nd, 3rd, and 4th base positions of the pentaloop (denoted 2AP-2, 2AP-3, 
and 2AP-4, respectively) were constructed by automated synthesis using 2-aminopurine-
TOM-CEphosphoramidite (Glen Research, Sterling, VA). Oligomers were deprotected 
and purified by 20% urea-PAGE. Purified oligomers were desalted on NAP-25 column 
and quantified by UV absorption at 260 nm. 
 
Steady-State Fluorescence Measurements.  
Steady-state fluorescence measurements were made on a Shimadzu RF-5301PC 
Spectrofluorophotometer as described. 21,26 Aliquots of concentrated stocks of free 
peptide or acridine-peptide conjugates were added stepwise to a stirred solution of 2AP-
containing RNA maintained at various temperatures in a series of buffer conditions. 
Fluorescence signal of 2AP was monitored at 370 nm with excitation at 310 nm. 
Dissociation constants (Kd) were analyzed  using the computer program Dynafit. 27 
 
Band Shift Analysis.  
Free boxB RNA or complexes of peptide-RNA were preformed in NMR buffer (50 
mM NaCl, 10 mM Phosphate, 0.5 mM EDTA, pH 6), and diluted by TBE buffer, before 
loading to 20% non-denaturing PAGE gel maintained at 10-15 °C. Free RNA and 
complex bands were visualized by UV shadowing. 
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One Dimensional NMR Spectroscopy.  
Unlabeled 15mer boxB RNA 5’GCCCUGAAAAAGGGC3’  (bases in the loop are 
underlined) was synthesized by in vitro transcription using T7 RNA polymerase.28 The 
RNA was purified by 20% urea-PAGE and desalted on a NAP25 column. Purified RNA 
oligomer was resuspended in NMR buffer (50 mM NaCl, 10 mM Phosphate, 0.5 mM 
EDTA, pH 6, 90:10 H2O/D2O). Spectra were collected on a Varian INOVA 600 MHz 
NMR spectrometer at 25 °C. Spectrum of free boxB RNA was collected first; titration of 
concentrated peptide or acridine peptide conjugate into the boxB RNA was monitored by 
inspecting the imino proton region of RNA. 
 
CD Spectroscopy.  
Spectra were taken on an Aviv 62 DS CD spectrometer at 20°C. The samples 
contained 5 µM RNA and 6 µM peptide in 10 mM potassium phosphate buffer (pH 7.9). 
The spectra of the bound peptides were determined by subtracting the spectra for free 
RNA and excess free peptide from that of the complex. 
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Results 
 
We envisioned that in the acridine peptide conjugate−RNA complex, the high affinity λ 
N peptide would bind to the major groove of the boxB RNA with the same structure as in 
the wild-type complex. 23,24 This would deliver the acridine moiety proximal to the 
bottom part of the RNA stem (Figure 1) where it can either intercalate into the stem or 
simply associate with the RNA extrahelically. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.   Design of acridine-peptide conjugate binding to boxB RNA. A. Sequences 
and secondary stem-loop structures of boxB RNA from λ  bacteriophages used in this 
study. B. Sequences of λ N22 full length and truncated λ N11 peptides. The 11-mer was 
tagged with gy for quantification purposes. C. Structure of acridine. D. Structure of 
linkers. 
N
A
A      A
G      A
U-A
C-G
C-G
C-G
G-C
G-C
17mer
λ-boxBR RNA N peptides
1                       11               18
λN22: MDAQTRRRERRAEKQAQWKAAN   λN11: MDAQTRRRERRgy
N
H
O
O
N
H
H
N
O
O
OLinker 1
Linker 2
  
12
Kd values. 
 Dissociation constants (Kd) were determined by monitoring the change in 
fluorescence of 2-aminopurine (2AP) incorporated at variable positions within the loops 
of the RNA hairpins. This base was found to be extremely useful as a probe of nucleic 
acid structure and dynamics,29 and RNA-peptide interactions.26 The fluorescence 
intensity of 2AP is very sensitive to local environment, decreasing when stacked and 
increasing when solvent exposed.30 In most cases, peptide binding can be detected by 
either a fluorescence increase or decrease of more than 20% from the starting value .21,31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Dissociation constants (Kd) for peptides and acridine-peptide conjugates against 
boxBR RNAa 
 λ boxBR RNA targets (17mers) 
 λ-2AP-2 λ-2AP-3 λ-2AP-4 
 
A 
A      A 
G      A 
U  A 
C  G 
C  G 
C  G 
G  C 
g   c 
A 
A      A 
G      A 
U  A 
C  G 
C  G 
C  G 
G  C 
g   c 
A 
A      A 
G      A 
U  A 
C  G 
C  G 
C  G 
G  C 
g   c 
Peptide Kd (nM) Kd (nM) Kd (nM) 
λN11 1126 1480 1000 
Acr-Link1-λN11 3945 2304 3504 
Acr-Link2-λN11 3082 2200 3245 
λN22 1.9 1.0  1.2  
Acr-Link1-λN22 2.7 1.3 2.0 
Acr-Link2-λN22 0.025b 0.019b 0.015b 
a Binding constants were determined for standard condition: 20 ˚C; 50 mM KOAc, 20 mM 
Tris.OAc, pH 7.5. Individual isotherms were fit to a one-step reaction with less than 
10% error. Hairpin base positions substituted with 2AP are underlined. Acr- refers to 
acridine moiety. 
b  Extrapolated from high salt measurement to 50 mM K+ (see Table 2 and Figure 2). 
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Table 1 shows the Kd values determined at 50 mM K+/20 mM Tris for acridine-λ N11, 
and acridine-λ N22 peptide conjugates, compared to those of WT peptides, against boxB 
RNA targets from λ phages. Binding affinities for truncated λ N11 peptide-acridine 
conjugates constructed with either a Gly-Gly linker 1 or an ethylene glycol linker 2 are 
similar to the WT λ N11 peptide. However, the binding affinities are enhanced when the 
longer and more flexible linker 2 is used on the full length peptide. The enhancement 
depends on the actual construct and RNA targets and the conjugates have increased 
binding specificity. For example, an acridine-full length peptide conjugate has 0.015 nM 
affinity to the 17mer boxB RNA with 2AP-4 labeling when extrapolated from high salt 
measurement to 50 mM K+ (Table 2, Figure 2), corresponding to a 80-fold enhancement 
over the wild full length peptide (1.2 nM). The longer and more flexible linker 2 seems to 
provide affinity enhancement. Full length acridine peptide conjugates constructed with 
the shorter and more rigid linker 1 exhibited no binding enhancement, therefore further 
investigations were focused on the linker 2.  
 
 
 
 
 
 
 
 
  
14
Salt dependence of binding.  
Generally protein-nucleic acid interactions become weaker as the salt concentration is 
increased due to the electrostatic nature of binding. This principle also extends to our 
system. Since N peptide is arginine-rich, the electrostatic interactions between positively 
charged peptide side chains and negatively charged RNA phosphate backbone are critical 
for binding.23 These electrostatic interactions are mitigated by increasing concentration of 
salt. Within a range of cation concentrations, plots of log (Kd) vs. log [M+] give a linear 
relationship. The slope of these plots corresponds to the number of counterions that are 
released upon peptide binding. In general, the slope is related to the net charge of the 
peptide and ranges from 2.5 to 5 for the N peptide sequences that have been tested.32  Salt 
dependence of acridine full length N peptide conjugate−boxB RNA complex was 
analyzed using the 17mer RNA with 2AP-4 labeling (Table 2, Figure 2). Most of the 
isothermal curves show biphasic transitions with the second transition starting after 
peptide conjugate reaches 1:1 stoichiometry with the RNA target. The Kd values were fit 
to the first transition. Indeed, higher salt decreased binding affinity of acridine-peptide 
conjugate to boxB RNA as observed for the WT peptide. The salt dependence graph 
showed linear relationship at higher salt and leveled off at low salt (Figure 2) as observed 
previously.33,34 The slope has a value of 2.9, slightly higher than the value of 2.4 for wild 
N peptide, indicating roughly three cations are released upon binding.  
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Figure 2. Salt dependence of λ full length peptide (diamond) and acridine-full length 
peptide conjugate (triangle) binding to 17mer λ boxB RNA (2AP-4). Measurements were 
made at 20 °C. 
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The Kd value extrapolated by salt dependence curve to 50 mM K+, 20mM Tris is 
0.015 nM. A roughly 80−fold binding enhancement was observed across a broad range of 
ionic concentrations. Since the conjugate has slightly higher slope of salt dependence 
than the free peptide, when extrapolated to lower salt, the enhancement is even higher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Salt dependence*  
 λ boxBR RNA target λ-2AP-4(17mer) 
 
A 
A      A 
G      A 
U  A 
C  G 
C  G 
C  G 
G  C 
g   c 
Total monovalent cation concentration ( mM) 
70 95 120 175 220 320 420 620 Peptide 
Kd (nM) 
λN22 1.2 1.9 4.2 8.5 19.8 43.5   
Acr-Link2-λN22     0.5 1.1 2.1 10 
* Total monovalent cation concentration is sum of K+ and Tris. Binding constants were 
determined for standard condition: 20 ˚C; 50-600 mM KOAc, 20 mM Tris.OAc, pH 7.5. 
Individual isotherms were fit to a one-step reaction with less than 10% error. Hairpin base 
positions substituted with 2AP are underlined. Acr- refers to acridine moiety. 
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CD Spectra.  
The CD spectra collected for both acridine-full length peptide conjugate and free full 
length peptide binding to boxB RNA (15mer) are shown in Figure 3. Neither the peptide 
nor the acridine-peptide conjugate shows any appreciable structure in the absence of 
RNA. The difference spectra of the two complexes indicate that both peptides fold into α 
helices when bound to the RNA. Although globally similar, the two complexes display 
some differences in regions indicative of peptide folding (200-225nm) and RNA folding 
(260-300nm). The acridine conjugate/RNA complex is less α-helical. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. CD spectra of free peptides and peptide/RNA complexes. 
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NMR Spectroscopy.  
NMR experiments can provide useful structural information on the boxB RNA 
(15mer) and N peptide, especially the structural change upon complexation. In particular, 
imino protons from RNA base pairs in the stem and Trp18 indole NH proton have unique 
signals that are easy to monitor. NMR spectra were collected in order to investigate the 
binding mode between acridine-peptide conjugate and the boxB RNA and compare to 
that of the free peptide and RNA (Figure 4). 
The free 15mer boxB RNA (Figure 4A, a) has 5 base pairs in the stem, the 1D imino 
proton NMR spectrum showed 3 peaks (13.25 ppm, 12.65 ppm, and 12.55 ppm) 
corresponding to the imino protons of G12, G13, and G14 from the three middle CG base 
pairs. The terminal GC pair is not observable due to fraying, and the U imino proton from 
loop closing UA pair is also missing presumably due to the flexibility of the unstructured 
pentaloop in the free RNA. Binding by either full length λ N22 peptide or truncated 
amino-terminal λ N11 induces similar RNA structural changes, evidenced by shifting of 
the three CG imino protons to higher field (Figure 4A, b and e). Beside these changes, 
there were additional imino protons at 13.5 ppm corresponding to U5 of the UA pair, and 
a broader peak at 10.7 ppm attributable to the G6 imino proton from the sheared GA base 
pair characteristic of GNRA tetraloop type of folding. This indicates that the loop has 
been stabilized by peptide binding. In addition, the Trp18 indole NH proton in the full 
length peptide has a large shift from 10 ppm (Figure 4A, d) in the free peptide to 9.2 ppm 
in the complex (Figure 4A, e), this is due to the stacking interaction between Trp18 and 
the RNA loop. 24 
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A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. One dimensional NMR spectra for peptide, boxB RNA, and complexes. A. 
Comparison of of λ N11 and λ N22  peptide/boxB 1:1 ratio complexes. B. Comparison of 
1:1 peptide/boxB complex and 2:1 peptide/boxB complex. The asterisk indicates the 
additional peak. 
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In comparison, the spectrum for acridine-λ N11 conjugate complexed to boxB RNA 
(Figure 4A, c) did not show these characteristic signal changes as observed in λ N11 
peptide/RNA complex, except for broadening of the original three peaks. This indicates 
that the acridine-λ N11 conjugate does not bind the RNA in the same mode as the λ N11 
peptide. Since acridine compound 2-acridin-9-ylamino-propanol binds to boxB RNA 
with about 15 µM affinity, similar to the affinity between λ N11 peptide and boxB RNA, 
it is possible that the two modules compete for the RNA binding site, and acridine moiety 
can associate with the RNA non-specifically, disrupting the specific complex structure 
between λ N11 peptide and boxB RNA. 
The spectrum for 1:1 acridine-full length peptide conjugate/boxB RNA complex 
(Figure 4A, f) showed very similar imino proton signals for RNA component and 
characteristic Trp18 indole proton shift as seen in the spectrum for λ N22 peptide 
complex. Within the acridine-full length peptide conjugate, it seems likely that the 
peptide portion binds the RNA in the same mode as in the WT λ N22 peptide complex. 
This should deliver the acridine moiety to the lower part of boxB RNA stem. 
Since acridine-full length peptide conjugate showed biphasic binding to boxB RNA, 
we further investigated the potential second binding site on boxB RNA for the conjugate. 
Over titration of the conjugate produced a 2:1 ratio of conjugate:RNA complex. 
Comparison of the spectra for 1:1 and 2:1 complexes of both WT peptide and acridine-
peptide conjugate revealed interesting discrepancies (Figure 4B). For the case of 2:1 
acridine-λ N22 peptide conjugate/boxB complex, the imino protons for U5 moved further 
down field, and G6 and G14 moved up field, respectively; furthermore, there is an 
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additional peak at 12.4 ppm. These features suggest a specific second binding site for the 
acridine-peptide conjugate. 
Band Shift Analysis.  
Observations from NMR experiments are consistent with the band shift analysis 
shown in Figure 5. Because the λ N11 peptide binds the boxB RNA specifically, a band 
shift can be observed (lane 2 of Figure 5A); while there is only smearing in the acridine-λ 
N11 peptide conjugate with boxB RNA (lane 3 of Figure 5A) indicating non-specific 
interaction, possibly random intercalation of acridine either in the stem or in the loop 
region which compete with the binding of peptide portion. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Gel shift analysis of peptide/boxB complexes for WT peptides and acridine-
peptide conjugates. A. λ N11/RNA and acridine-λ N11/RNA complexes. B. λ N22/RNA 
and acridine-λ N22/RNA complexes. 
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No peptide     λN(1-11) Acridine-λN(1-11)
1                      2                      3
B
Free RNA
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No       λ N(1-22) Acridine-
Peptide                     Conjugate
1           2          3
Peptide
Lane
15mer boxB RNA
  
22
 
The acridine full length conjugate, however, not only showed a 1:1 complex to boxB 
RNA 15-mer (lane 3 of Figure 5B) as in peptide-RNA complex (lane 2 of Figure 5B), but 
a higher stoichiometric complex as well. These results suggest that there is a second 
binding site for the acridine-peptide conjugate. This may explain the profile of the 
fluorescence titration curves, which sometimes show biphasic transitions with the second 
transition apparently following equimolar titration. 
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Discussions 
To achieve higher RNA binding affinities, the design of a ligand consisting of two 
moieties connected by a linker is a promising approach. 7,8 Higher binding affinities could 
result from a favorable entropic factor compared with the binding of the two monomeric 
counterparts. Sometimes the length and nature of the linker is critical. The molecule can 
be a dimeric form of a known binder 35 or can consist of two distinct moieties that bind to 
RNA in different modes, e.g., groove binding and intercalation.10-12 To apply this idea to 
the N peptide system, a series of λ N peptide-based peptide-acridine conjugates were 
designed and synthesized. Their binding affinities to boxB RNAs with stem-loop hairpin 
structures were determined by steady-state fluorescence measurements. 
Since acridine compound 2-acridine-9-ylamino-propanol binds boxB RNA with 15 
µM affinity, theoretically, it can provide up to three orders of magnitude enhancement 
when linked to another binding module. The full enhancement may never be realized in 
real systems. From comparing salt dependence of binding, acridine-peptide conjugation 
showed 80-fold binding enhancement over a broad range of salt concentrations. This 
result is similar to binding enhancement observed for a neo-acridine construct over 
neomycin B alone binding to RRE RNA.12 The same construct showed 3-fold tighter 
binding to a related P22 boxB RNA target. Compared to λ boxB, this RNA has 
orientation of one base pair in the stem flipped, and a cytidine in the loop instead of 
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adenine (Figure 6). Both λN22 and P22N21 full-length peptides discriminate strongly 
between their cognate RNA hairpins and other boxB targets.32 The acridine-peptide 
conjugates showed enhanced binding specificity between these two similar RNA 
structures (Table 3). Therefore, the actual enhancement by acridine conjugation depends 
on the targets involved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Dissociation constants (Kd) for peptides and acridine-peptide 
conjugates against λ boxB and P22 boxBR RNAa 
 boxBR RNA targets (17mers) 
 λ-2AP-4 P22-2AP-4 
 
 
A 
A      A 
G      A 
U  A 
C  G 
C  G 
C  G 
G  C 
g   c 
 
C 
A      A 
G      A 
U  A 
C  G 
G  C 
C  G 
G  C 
g   c 
Peptide Kd (nM) Kd (nM) 
λN22 1.2 257 
Acr-Link2-λN22 0.015b 80 
a Binding constants were determined for standard condition: 20 ˚C; 50 
mM KOAc, 20 mM Tris.OAc, pH 7.5. Individual isotherms were fit 
to a one-step reaction with less than 10% error. Hairpin base 
positions substituted with 2AP are underlined. Acr- refers to 
acridine moiety. 
b  Extrapolated from high salt measurement (Figure 2) 
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A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
Figure 6. Comparison of  λ boxB and P22 boxB RNA. (A) Structural models of phage λ 
and P22 N peptide-boxB hairpin complexes viewed from the major groove. In all 
complexes the N peptide is shown as a ribbon; (B) Schematic representation of 
λ  and P22 boxB hairpin stem-loop structure.  
A
A      A
G      A
U-A
C-G
C-G
C-G
G-C
G-C
λ-boxB 17mer
C
A      A
G      A
U-A
C-G
G-C
C-G
G-C
G-C
P22-boxB 17mer
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Homologous hydrophobic interactions occur between the boxB hairpin stem and 
conserved alanine residues within the N peptide amino-terminal module. Distinct 
hydrophobic interactions appear between the boxB hairpin loops and carboxy-terminal 
modules of the N peptides. In λ, a tryptophan residue stacks on the boxB loop; in P22, 
non-polar alanine and isoleucine residues interact with an extruded pyrimidine. In phage 
λ and P22, the bound pentaloops adopt stable GNRA tetraloop folds by extruding either 
loop base 4 (4-out) in the λ complex, or loop base 3 (3-out) in the P22 complex.  
In contrast, conjugation of acridine to the λ N11 peptide did not improve binding. In 
fact, the conjugate bound about 3-fold weaker than the λ N11 peptide alone. The NMR 
and gel shift data showed that the conjugate does not form a specific complex with boxB 
RNA (Figure 4A and 5A). Presumably this is due to the fact that the acridine moiety has 
similar affinity to the boxB RNA compared to the the λ N11 peptide, and acridine binding 
is non-specific. Therefore the acridine moiety competes the binding sites of RNA 
structure with peptide moiety. This result suggests that when designing a ligand with 
multiple binding modules, it is important to avoid a non-specific binding module that can 
compete multiple sites intended for the other modules. A module with higher affinity for 
one site will help anchor the entire ligand. The specific binding peptide module of the full 
length acridine-peptide conjugate has much higher affinity for the λboxB RNA, the 
peptide portion maintains all the native contacts with RNA (Figure 4A), and the acridine 
moiety can be specifically delivered to the intended site. 
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Previous structural studies on DNA intercalated with acridine related compounds 
have consistently shown intercalation site at alternating base steps, particularly at the 
terminal base steps.36 This is likely due to the fact that terminal base steps have much 
greater conformational freedom than internal base steps, which facilitates intercalation. 
Recent studies on DACA, an antitumor acridine derivatized with variable functional 
substitutions at position 4, showed that they intercalate into DNA with side chains lying 
in the major groove.37-39 However, the crystal structure of an acridine-tetraarginine 
conjugate with the peptide attached to the position 9 showed intercalation of acridine into 
the minor groove of central AA/TT base step of a long DNA fragment, leaving the 
peptide lying in the minor groove.40 
In these cases, it appeared that specific hydrogen bonding interactions between the 
lateral chain of acridine and DNA may affect how the acridine moiety intercalates into 
nucleic acids.  Interestingly, a recent study also showed that in peptide-acridine 
conjugates, the point of attachment on acridine affects the conjugates’ affinity for nucleic 
acid target.41 
Our acridine-N peptide conjugates feature the peptide portion attaching to the 
acridine at position 9, similar to the acridine-tetraarginine case.  To determine the precise 
binding mode of acridine in these conjugates is challenging at this time. There may be 
multiple reasons for this.  If the acridine moiety derivatized at position 9 with a peptide  
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prefers intercalation from minor groove as in the case of acridine-tetraarginine,40 our 
construct may preclude intercalation, because full length N peptide binds boxB RNA in 
the major groove with high affinity. In the case of the acridine-λ N11 conjugate, the 
acridine may be able to intercalate into minor groove, but this intercalation is probably 
non-site-specific. A second reason is that once the N peptide (especially the full length) 
binds to boxB RNA peptide induces RNA folding. There are extensive interactions 
between peptide and RNA stem, an intercalated acridine moiety in the stem may disrupt 
specific interactions between RNA and peptide. However, the acridine may still be able 
to intercalate at the terminal base step, but since the imino proton from the terminal base 
pair is not observable, this possibility has not been confirmed. 
Similar to the neo-acridine case12 where there was a second binding site, our 
fluorescence, NMR, and gel shift data also suggested a second specific binding site for 
acridine-N peptide conjugate on boxB RNA. The nature of the second site is not known, 
but it may be in either the major or minor groove. Changes of the imino proton chemical 
shifts can be observed throughout the RNA structure (Figure 4B), suggesting that the 
interactions may be extensive. 
Other approaches of enhancing RNA binding affinity may also be available. N 
peptides bind boxB RNA in an α-helical conformation, but have little helical structure 
when free in solution.25 Stabilizing the helical form of such peptides is expected to favor 
RNA binding by virtue of pre-organization. For example, Cα-substituted amino acids has 
long been recognized as a means of introducing local conformational restriction in 
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peptides.42 Another approach to stabilize the α-helical form of peptides is through the 
incorporation of covalent linkages between constituent amino acid side chains. It was 
found that substantial helix stabilization was achieved when the linkage was placed 
between the i and i+4 residue in the peptide backbone by ring closing metathesis.43-46 
Therefore, cyclic helical N peptides, wherein ring closing metathesis is used to 
incorporate a carbon-carbon tether between appropriate residue side chains, is expected to 
provide binding enhancement. This approach provides a convenient way to enhance the 
affinity of known modules and facilitates the discovery of powerful new hybrid ligands 
with new functionalities. 
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Conclusion 
 
Designing ligands that consist of multiple modules for binding RNA targets can be a 
powerful approach to achieve high affinity and specificity. A series of full-length or 
truncated acridine-peptide conjugates based on the N peptide of bacteriophage λ were 
designed and synthesized. Their binding affinities to a series of Box B RNAs with stem-
loop hairpin structures were determined using steady-state fluorescence measurements. 
Thermodynamic parameters have been characterized for these complexes using salt 
dependence. An 80-fold binding enhancement of acridine-peptide conjugate with Box B 
RNA was exhibited across a range of salt concentrations. NMR, gel shift, and CD data 
also indicated the N peptide-acridine conjugate/Box B RNA complex formation. 
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Chapter 2 
Creating Synthetic “Blanks” in the Genetic Code Using A 
Novel Class of Aminoacyl Adenylate Mimics as tRNA 
Synthetase Inhibitors  
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Abstract 
Efforts to reengineer the protein synthesis apparatus should expand our fundamental 
understanding of the central macromolecular synthesis machinery inside all cells.  The 
UAG stop codon has often been referred to as a “blank” in the genetic code because it 
can be suppressed by an appropriate tRNA.  We would like to eliminate the activity of 
specifically chosen aminoacyl tRNA synthetase (aaRS), creating our own blanks in the 
codes.  We generated various high-affinity inhibitors of the synthetases—aminoacyl 
sulfamide to create synthetic blanks in our translation extracts.  The gaps were filled with 
chemically aminoacylated orthogonal tRNAs.  This unnatural strategy enables peptides 
and proteins to be constructed containing a single novel residue at a specific location. 
Biocytin, a biotin derivative of lysine, can be incorporated into globin, efficiently 
enriched by using aminoacyl sulfamide to inhibit natural aminoacylated tRNA and 
adding orthogonal tRNA coupled with biocytin. 
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Introduction 
 
The protein synthesis machinery translates genetic information into folded, functional 
polypeptides, but is constrained by the universal genetic code to using the 20 naturally 
occurring amino acids as building blocks. Each of these 20 amino acids is escorted into 
the machine by transfer RNA that recognizes a specific codon in a message RNA 
template (Figure 1).  Rewriting genetic code requires reassigning the codons to 
correspond to new amino acids. 
 
 
 
 
 
 
 
 
 
Figure 1. The protein synthesis machinery - ribosome. 
 
The incorporation of unnatural amino acids into peptides and proteins has been 
pursued intensively over a couple of decades. Several unnatural amino acids have been 
incorporated into dipeptides through the use of chemically misacylated tRNAs in the 
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Hecht lab1.  The UAG stop codon has often been referred to as a “blank” in the genetic 
code because it can be suppressed by an appropriate suppressor tRNA. Schultz and 
coworkers demonstrated the insertion of unnatural amino acids into proteins by nonsense 
UAG suppression2,3.  While the original description of the method utilized an E. coli 
translation extract, the technique has been applied to eukaryotic translation extracts such 
as rabbit reticulocyte lysate4-7 or in vivo in Xenopus oocytes8-10.  This unnatural strategy 
enables peptides and proteins to be constructed containing a single novel residue at a 
specific location, amenable to the insertion of various entities into proteins including: 1) 
affinity tags, 2) spectroscopic probes, and 3) various amino acid derivatives for physical 
organic and mechanistic studies of protein function.   
  We would like to create our own blanks in the code by eliminating the activity of 
specific aaRS as we choose.  All aaRSs act by using ATP to create an activated form of 
an amino acid − a mixed carbon-phosphorus anhydride termed an aminoacyl adenylate 
(Figure 2).  Aminoacyl sulfamides are stable structural mimics of aminoacyl adenylates 
and generally have submicromolar Ki values for their corresponding synthetases11.  We 
generated various high-affinity inhibitors of the synthetases to create synthetic blanks in 
our translation extracts.  Aminoacyl tRNA synthetase inhibitors are combined with 
translation extracts and chemically aminoacylated orthogonal tRNAs to reprogram 
specific codons as desired. The genetic code will be determined by the chemically 
acylated tRNAs used, rather than by the natural aminoacyl-tRNA synthetases, the 
gatekeepers of the genetic code.   
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Figure 2. (A) Aminoacyl tRNA synthetases (aaRSs) specifically catalyze the 
aminoacylation of tRNA in a two step reaction. (B) The tRNA synthetases typically 
catalyze the formation of tightly bound aminoacyl-adenylates in their first reaction step. 
The analogues of these reaction intermediates (aminoacyl sulfamides) have been 
synthesized and evaluated for the ability to inhibit aminoacylation. 
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Application of non-sense and sense-codon suppression in protein selection has been 
examined in our group12,13. First, we reported that biocytin, a biotin derivative of lysine, 
can be inserted into an mRNA-protein fusion molecule through amber stop codon 
suppression. We also demonstrated that templates containing the codon corresponding to 
the biocytin tRNA (a UAG stop codon) can be enriched by iterative cycles of selection 
against a streptavidin agarose matrix. The universal genetic code links the 20 naturally 
occurring amino acids to the 61 sense codons. We have developed a selection 
methodology to investigate whether the unnatural amino acid biocytin could be 
incorporated into an mRNA display library at sense codons. In these experiments we 
probed a single randomized NNN codon with a library of 16 orthogonal, biocytin-
acylated tRNAs. In vitro selection for efficient incorporation of the unnatural amino acid 
resulted in templates containing the GUA codon at the randomized position. This sense 
suppression occurs via Watson-Crick pairing with similar efficiency to UAG-mediated 
nonsense suppression. These experiments suggest that sense codon suppression is a 
viable means to expand the chemical and functional diversity of the genetic code.  We 
envision that these aaRS inhibitors should facilitate the construction of novel proteins and 
selection of unnatural amino acids incorporated by sense codon suppression using the 
mRNA display approach (Figure 3).   
  
43
mRNA display provides a strategy to make up to 1013 unique peptides that fuse with 
their own genes via a covalent linkage.  Compared to other in vitro selection 
methodologies, such as phage-display14,15 and  surface-display16 libraries, mRNA 
display17,18 libraries have several unique features, including the incorporation of 
unnatural residues, the chemical derivatization of libraries, and the feasibility of 
mutagenic PCR and DNA recombination.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Selection cycle via mRNA display17. 
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In affinity selection with mRNA display library, the synthetic DNA library is 
transcribed to make mRNA, which is modified with a 3’-puromycin. The engineered 
mRNA template is translated to prepare mRNA-peptide fusion. After a cDNA•mRNA 
duplex is generated by reverse transcription, the fusion library is subjected to affinity 
selection against targets of interest. The enriched library is amplified by PCR for the next 
cycle of selection. 
Biocytin can be detected by ECL Plus Western Blotting Detection, and it binds to 
streptavidin (protein) coupled with Horseradish Peroxidase (HRP enzyme) which 
catalyzes a chemoluminence reaction. 
 
 
 
 
 
 
 
 
 
Figure 4. Biocytin charged suppressor tRNA and biocytin structure. 
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for THG73, which was mutated at the tRNA anticodon position by Quikchange 
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carboxylic group was activated by acetonitrile. The activated amino acid was then 
coupled to dinucleotide pdCpA.  Using T4-RNA ligase, dinucleotide pdCpA coupled 
with unnatural amino acid was ligated to the engineered truncated 73-nucleotide tRNA to 
form intact charged suppressor tRNA. Right before applying it to the translation system, 
NVOC protecting group was deprotected using UV irradiation (Scheme 1). 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Preparation of amino acylated THG73 tRNAs. 
Since various high-affinity inhibitors of the synthetases suppress the formation of 
natural amino acylated tRNA and create synthetic blanks in our translation extracts, the 
selection rounds will be shortened for the discovery of novel ligands with functionalities 
beyond those provided by the 20 naturally occurring amino acids. 
NH
R
O
O
O
O
NO2
O
O
N
H2N
R
OH
O
NVOC-Cl chloroacetonitrile
ligation
T4-RNA ligaseUV
N
NH2
ON
O
O
P
O
O-O
N
NN
N
NH2O
OP
O
O-O
OHNO
O
O2N
O
O
R
-O
OH
O
C
O
CH
NH3+
R
dCA
UA
A AU
G
U
CC
C
GG
GU
U
A
A
A U
G
U
U
UC
C AAA
A
CUGG
CG
G
U
C
UG
CAU
U U
G
G
CA
A
G
C G
A C
U
C
GG
C
U
UU
U AA
G
GG
G G
C
C
C
X X X
  
46
Materials and Methods 
 
General Information.  1H and 13C NMR spectra were recorded on a UNITY INOVA 
instrument (Varian, Inc.) operating at 500 MHz using D2O or DMSO-d6 as the solvent.  
1H NMR data are reported as follows:  s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; br s, broad singlet; dd, doublet of doublets.  High-resolution mass spectra 
(FAB) were recorded on a JMS-600H double-focusing, high-resolution, magnetic sector 
mass spectrometer ( Mass Spectrometry Laboratory, Division of Chemistry and Chemical 
Engineering, California Institute of Technology).  Column chromatography was carried 
out on silica gel (40-63 µm, EM Science).  All reagents were of highest available 
commercial quality and were used without further purification.  Triphenolphosphine, 
phthalimide, 2’,3’-O-isopropylideneadenosine, hydrazine, benzyl alcohol, diethyl 
azodicarboxylate, chlorosulfonyl isocyanate, Pd 10% on activated carbon wet Degussa 
type, carbonyldiimidazole and diazabicycloundecene were purchased from Aldrich.  
Sodium azide was purchased from Sigma Chemical Co.  Boc-Ala-OH, Boc-Val-OH, 
Boc-Leu-OH, Boc-ILe-OH, Boc-Phe-OH, Boc-Trp-OH, Boc-Tyr(2-Br-Z)-OH, Boc-Met-
OH, Boc-Pro-OH and Boc-Gly-OH were purchased from Novabiochem.     
Rabbit reticulocyte lysate was purchased from Novagen.  Rabbit globin mRNA was 
obtained from Sigma Chemical Co. Ras mRNA was prepared by using two DNA primers 
complementary  to the 5’- and 3’- ends of the coding region for  H-Ras (  pProEX HTb  
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vector, a kind gift from Dafna Bar-Sagi)19 to amplify the gene using PCR.    mRNA was 
produced by T7 runoff transcription20 of the H-Ras DNA in the presence of RNAsecure 
(Ambion) followed by gel purification via denaturing urea-PAGE and ‘crush and soak’ 
RNA isolation.  L-[35S]methionine (1,175 Ci/mmol) was purchased from NEN Life 
Science Products.  GF/A glass microfiber filters were from Whatman.  Scintillation 
counting was carried out using a Beckman LS-6500 liquid scintillation counter. 
 
General Procedure for Preparation of Aminoacyl-Sulfamides.  5’-Amino-2’, 3’-
O-isopropylidene -5’-deoxyadenosine was prepared from commercially available 2’,3’-
O-isopropylideneadenosine via the procedure disclosed previously21.  It was then 
converted to 5’-deoxy-2’, 3’-O-isopropylideneadenosine-5’-N-[(phenylmethoxy) 
carbonyl]-sulfamide by treatment with N-carbobenzyloxysulfamoyl chloride and a base 
such as triethylamine in dichloromethane at 0 °C to ambient temperature.  CBZ protected 
sulfamide was reduced with Pd 10% on activated carbon wet Degussa type and hydrogen 
gas in EtOH/MeOH to afford 5’-deoxy -2’, 3’-O-isopropylideneadenosine-5’-N-
sulfamide, which was further reacted with BOC protected amino acids catalyzed by 
carbonyldiimidazole and base diazabicycloundecene in acetonitrile.  The obtained  5’-
deoxy-2’,3’-O-isopropylideneadenosine-5’-N-(N-tertbutoxycarbonyl-aminoacyl) 
sulfamides were fully deprotected according to standard procedures and purified by 
trituration22.  
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IC50 determination.  Translation reactions containing [35S]Met were mixed in batch 
on ice and added in aliquots to microcentrifuge tubes containing an appropriate amount 
of aminoacyl-sulfamide (2.5 µL of different concentrations).  Typically, a 25 µl 
translation mixture consisted of 1.0 µL of 2.5 M KCl, 0.5 µL of 25 mM MgOAc, 2.0 µL 
of 12.5X translation mixture without methionine, (25 mM dithiothreitol (DTT), 250 mM 
HEPES (pH 7.6), 100 mM creatine phosphate, and 312.5 µM of 19 amino acids, except 
methionine) (Novagen), nuclease-free water, 2.0 µL (6.1 µCi) of [35S]Met (1175 
Ci/mmol), 10 µL of Red Nova nuclease-treated lysate (Novagen), and 5 µL of 0.05 
µg/µL globin mRNA (Sigma).  Inhibitor, lysate preparation (including all components 
except template), and globin mRNA were mixed simultaneously and incubated at 30 ºC 
for 60 min.  Biocytin-tRNAs were added for translation restoration test.  Then 2 µL of 
each reaction was combined with 8 µL of tricine loading buffer (80 mM Tris-Cl (pH 6.8), 
200 mM DTT, 24% (v/v) glycerol, 8% sodium dodecyl sulfate (SDS), and 0.02 % (w/v) 
Coomassie blue G-250), heated to 90 ºC for 5 min, and applied entirely to a 4% stacking 
portion of a 16% tricine-SDS-polyacrylamide gel containing 20% (v/v) glycerol  (30 mA 
for 1h, 30 min)23.  Gels were fixed in 10% acetic acid (v/v) and 50% (v/v) methanol, 
dried, exposed overnight on a PhosphorImager screen, and analyzed using a Storm 
PhosphorImager (Molecular Dynamics).  Inhibition of translation to a variety mRNA  
templates was tested in a similar condition. 
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Preparation of biocytin-acylated tRNAs.  The pUC19-based plasmid harboring the 
gene for THG73 was mutated at the tRNA anticodon position by Quikchange 
(Stratagene).   Resulting clones were verified by DNA sequencing before synthesizing  
individual tRNAs by in vitro transcription with T7 polymerase from Fok I-linearized 
plasmids.  Transcribed tRNAs were then gel-purified and desalted by ethanol 
precipitation.  Purified tRNAs were ligated to NVOC protected biocytin-dCA with T4 
RNA ligase (New England Biolabs).  Reaction mixtures were extracted in an equal 
volume of phenol:CHCl3:isoamyl alcohol (25:24:1, pH 5.2, Fisherbiotech), and 
precipitated with 3.0 volumes of cold ethanol (-20 °C).  After drying, the pellets were 
resuspended in 1.0 mM sodium acetate, pH 5.2, and adjusted to 4.0 mg/mL and 1.0 
mg/mL for each biocytin-acylated tRNA.  Biocytin-tRNA concentrations were 
determined by UV absorbance at 260 nm.  Before adding to translation reactions, 
biocytin-tRNAs were deprotected by a xenon lamp outfitted with a 315 nm cut-off filter 
for 5 min to remove the NVOC group. 
 
Restoration of Translation Probed with Streptavidin-capture of Biocytin-
containing Globin.  A portion of streptavidin-agarose (0.75 mL) [Pierce, 50% slurry 
(v/v)] was washed 3 times with a buffer (1X PBS containing 0.1% Triton X-100) and 
resuspended in 0.75 mL of buffer.  To 100 µL of this suspension, 10 µL of the translation 
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 reaction and up to 0.7 mL of buffer were added.  The samples were rotated at 4 ºC for 
1.5 h and washed with buffer until the cpm of [35S]Met were <500 in the wash.  
Immobilized [35S]Met-biocytin-containing-globin was eluted by adding tricine loading 
buffer (80 mM Tris-Cl (pH 6.8), 200 mM DTT, 24% (v/v) glycerol, 8% sodium dodecyl 
sulfate (SDS), and 0.02 % (w/v) Coomassie blue G-250) (50 µL for each sample) directly 
to the streptavidin-agarose beads with heating at 90 ºC for 10 min.  The amount of 
immobilized [35S]Met-biocytin containing globin was determined by scintillation 
counting of the eluent (Figure 10).    
      
Restoration of Translation Probed by Western Blot Analysis.  A portion of each 
translation reaction (2 µL) was combined with 8 µL of tricine loading buffer, heated to 90 
ºC for 5 min, and applied entirely to a 4% stacking portion of a 15% SDS-polyacrylamide 
gel.  The protein was transferred to nitrocellulose membrane in 1X transfer buffer w/ 
10% MeOH (10X transfer buffer: Glycine 290g, Tris base 58g to 2L H2O) using 
Miniprotean II wet transfer apparatus (Bio-Rad).  The nitrocellulose membrane was 
blocked w/ 1% BSA in 1X PBS +0.1% Tween-20 for 1h and probed with Streptavidin-
HRP conjugate (1:2000) for 1h.  The membrane was washed four times with 30ml 1X 
PBS-T and visualized using ECL plus Western Blotting Detection System (Amersham 
Biosciences).   Luminescence was then detected using HyperfilmTM (Amersham) with 
various exposure times.   
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Results 
 
We generated various high-affinity inhibitors of the tRNA synthetases—aminoacyl 
sulfamides to create synthetic blanks in our translation extracts. We demonstrated that we 
can create and reprogram synthetic “blanks” in the genetic code. Aminoacyl tRNA 
synthetase inhibitors were combined with translation extracts and chemically 
aminoacylated orthogonal tRNAs to reprogram specific codons as desired. 
 A series of aminoacyl sulfamides were synthesized starting from 2’, 3’-O-
isopropylidene adenosine21,22  (Scheme 2). 5’-hydroxy to amino group transformation 
was achieved by reacting with phthalimide followed by reducation using hydrazine. The 
first step reaction was catalyzed by Diethyl azodicarboxylate EtO2CN=NCO2Et and 
triphenylphosphine. 5’ free amino group reacted with N-Benzyloxycarbonylsulfamoyl 
chloride to afford protected aminoacylsulfamide. Deprotection using Pd catalyzed 
hydrogenation gave adenosine-5’-N-sulfamide which was coupled with Boc-protected 
amino acids catalyzed by CDI (carbonyldiimidazole) and DBU (diazabicycloundecene).  
After Boc protecting group was deprotected using TFA condition, the residue was 
triturated with anhydrous ether to give aminoacyl sulfamide as a white solid. There are 
additional procedures according to different amino acids with more complex side chains. 
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Scheme 2. Synthesis of aminoacyl sulfamides. 
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Addition of micromolar concentrations of synthetically constructed sulfamides allows 
us to specifically block the action of one or more synthetases as we choose. Inhibition is 
general to a variety of templates we tested, such as globin, Ubiquitin, and Ras mRNA 
templates (Figure 5).  Clearly the potency of different aminoacyl sulfamides to inhibit 
protein translation varies according to the amino acid bearing and the mRNA template 
tested. 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Inhibition of protein translation by aminoacyl-sulfamide. Tricine-SDS-PAGE 
analysis of [35S]Met-protein translation reactions in the presence of 1 µM of aminoacyl-
sulfamides. 
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We then measured the activity of each compound in a high dynamic-range IC50 
potency assay using the rabbit reticulocyte protein synthesis system.24 The various 
aminoacyl sulfamides inhibit globin translation with IC50 in the range of 22 nM to 28 µM 
(Figure 6). There appears to be a general correlation between the potency of the drugs 
and the amino acid abundance for a particular template. For example, Leu-sulfamide is a 
very potent inhibitor (IC50 22 nM), whereas Ile-sulfamide is a poor inhibitor (IC50 6.7 
µM) for globin translation, and there are more positions coded for Leu (17/18) than Ile 
(3/1) in globin template. Presumably, the larger abundance of an amino acid in the 
template, the easier to inhibit the translation by shutting down the aminoacyl tRNA 
synthetase activity. All inhibitors are specific to corresponding aminoacyl tRNA 
synthetases due to the structural similarity to their corresponding aminoacyl adenylates. 
A key issue is whether we can restore translation of globin by supplying aminoacyl 
tRNAs orthogonal to the codon blank created by the inhibitor. We tested the restoration 
of globin translation by biocytin-tRNAs coding for valine (Figure 7). We used an 
orthogonal tRNA charged with biocytin to eliminate it as a substrate for the cognate 
aminoacyl-tRNA synthetase and provide an easy handle for probing.  
 
 
 
  
55
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inhibition of globin translation by aminoacyl sulfamide. (A) Tricine-SDS-
PAGE analysis of [35S]Met-globin translation reactions in the presence of Leu-Sulfamide:  
Lane 1, no template; lane 2, globin alone; lanes 3-10, concentrations of aminoacyl 
sulfamide from 0.1 nM to 10 µM.  (B) Percent globin translation relative to the no drug 
control for Leu-Sulfamide from gel analysis of (A).  (C) IC50 values for various 
aminoacyl sulfamides. 
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The total globin translation level with the Val-sulfamide inhibitor and biocytin-
tRNAs coding for valine is shown in Figure 7. At 1 µM of val-sulfamide, we were able to 
reduce the translation level to ~10% (lane 3). In the presence of biocytin-tRNAs, globin 
translation was restored to about 40% relative to no drug translation, depending on which 
biocytin-tRNAs were added (lane 4-6). 
 
  
 
 
 
 
 
 
 
 
 
Figure 7.  Globin translation restoration by biocytin-tRNA THG73 variant containing 
anticodon CAC, AAC or GAC in the presence of Val-sulfamide inhibitor: Lane 1, no 
template; lane 2, globin alone; lane 3, 1µM of val-sulfamide; lanes 4 - 6, biocytin-tRNA-
CAC, GAC or AAC was added individually.  
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there are 10 valine codons, all are GUG (anticodon CAC); in β-globin, there are 18 valine 
codons, 12 of them are GUG, and 2 GUC (anticodon GAC) and 4 GUU (anticodon 
AAC), no GUA. The globin bands may represent heterogeneous populations of biocytin 
incorporation and the more abundant codon sites (lane 4, CAC) are over-represented than 
less abundant codons (lane 6 GAC, lane 7 AAC).  Also when we use biocytin–tRNA with 
stop codon UAG (lane 5, anticodon CUA), there is no significant biocytin incorporation, 
and this demonstrates that the Val sulfamide inhibitor shows specificity toward the 
corresponding Val synthetase due to the structural similarity.  
 
 
 
 
 
 
 
 
Figure 8.   Globin Translation Restoration probed with Western blot.  Lane 0, precision 
protein standard unstained; lane 1, no template; lane 2, globin alone; lane 3, 1µM of val-
sulfamide; lane 4, biocytin-tRNA-CAC  (Valine codon GUG); lane 5, biocytin-tRNA-
CUA (stop codon UAG); lane 6, biocytin-tRNA-GAC  (Valine codon GUC); lane 7, 
biocytin-tRNA- AAC  (Valine codon GUU) was added individually. 
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We further compared biocytin incorporation level in the presence and absence of Val-
sulfamide. As shown in Figure 9, biocytin incorporation level in the presence of the 
inhibitor (lane 6 and 7) is higher than that in the absence of the inhibitor (lane 4 and 5).  
This suggests that the presence of the inhibitor provides enhancement of unnatural amino 
acids incorporation. 
 
 
 
 
 
 
 
 
Figure 9.   Globin Translation Restoration probed with Western blot in the presence of 
inhibitor and in the absence of inhibitor.  Lane 0, precision protein standard unstained; 
lane 1, no template; lane 2, globin alone; lane 3, 1 µM of Val-sulfamide; lane 4, biocytin-
tRNA-AAC was added without the inhibitor; lane 5, biocytin-tRNA-CAC was added 
without the inhibitor: lane 6, biocytin-tRNA-AAC in the presence of 1 µM of Val-
sulfamide; lane 7, biocytin-tRNA-CAC in the presence of 1 µM of Val-sulfamide. 
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We also tested the restoration of globin translation by biocytin-tRNAs coding for 
valine probed with Streptavidin-capture of biocytin-containing globin.  [35S]Met-
biocytin-containing-globin was immobilized to streptavidin-agarose beads and then 
eluted by adding tricine loading buffer directly to the streptavidin-agarose beads with 
heating at 90 ºC for 10 min. The amount of immobilized [35S]Met-biocytin containing 
globin was determined by scintillation counting of the eluent (Figure 10).  This also 
demonstrated that in the presence of biocytin-tRNAs, globin translation was restored to 
about 35-40% relative to no drug translation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Restoration of translation probed with streptavidin-capture of biocytin-
containing globin. 
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Discussions 
tRNA synthetase inhibitors enhance In Vitro suppression  
In this work, we prepared a series of aminoacyl-adenylate analogues and evaluated 
their potency for inhibition of protein translation. Further, we characterized the ability of 
aminoacyl sulfamides to facilitate incorporation of an unnatural amino acid, biocytin, into 
globin protein.  This approach provides a facile means to rewrite the universal genetic 
code at will, without extensively re-engineering cells. Therefore, this work provides an 
experimental means to pursue fundamental questions relating to the construction, 
functional diversity, and organization of the genetic code (Figure 11).  
 
 
 
 
 
 
 
 
 
 
Figure 11.   Enhance In Vitro suppression by tRNA synthetase inhibitors. 
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Uniting mRNA display, In Vitro Suppression and tRNA synthetase inhibitors 
The incorporation of unnatural amino acid into selectable, amplifiable peptide and 
protein libraries expands the chemical diversity of such libraries, thus considerably 
facilitating the process of obtaining ligands with improved properties (affinity, specificity, 
and function), particularly against therapeutically interesting targets. Here we also 
demonstrated that sense codon suppression was enhanced by tRNA synthetase inhibitors. 
To apply this unnatural strategy to selection cycle via mRNA display library, we can 
facilitate the enrichment of desired unnatural amino acid residue and speed up the 
selection process (Figure 12). 
 
 
 
 
 
 
 
 
 
Figure 12. Selection cycle via mRNA display enhanced by tRNA synthetase inhibitor. 
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Conclusions 
We generated various high-affinity inhibitors of the tRNA synthetases—aminoacyl 
sulfamides to create synthetic blanks in our translation extracts. Aminoacyl tRNA 
synthetase inhibitors were combined with translation extracts and protein translation was 
shown to be inhibited. We then measured the activity of each compound in a high 
dynamic-range IC50 potency assay using the rabbit reticulocyte protein synthesis system. 
The various aminoacyl sulfamides inhibit globin translation with IC50 in the range of 22 
nM to 28 µM. 
We further demonstrated the restoration of globin translation by biocytin-tRNAs 
coding for valine in the presence of Val-sulfamide inhibitor. Here, specific biocytin 
incorporation was probed by Western blot, and biocytin incorporation level in the 
presence of inhibitor is higher than that in the absence of inhibitor.  This suggests that the 
presence of inhibitor provides enhancement of unnatural amino acids incorporation. 
In this work, we demonstrated that we can create and reprogram synthetic “blanks” in 
the genetic code. Most importantly, we can facilitate the enrichment of desired unnatural 
amino acid residue and speed up the selection process when we unit mRNA display, in 
vitro Suppression and tRNA synthetase inhibitors. 
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Chapter 3 
Probing Flexibility of Protein Synthesis In Vitro by 
Puromycin Analogs  
 
 
 
 
 
 
 
 
Part of this work has previously appeared as: Starck, S. R., Qi, X., Olsen, B. N. & 
Roberts, R. W. The puromycin route to assess stereo- and regiochemical constraints on 
Peptide bond formation in eukaryotic ribosomes. J Am Chem Soc 125, 8090-1 (2003). 
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Abstract 
Puromycin is a small-molecule mimic of aminoacyl-tRNA (aa-tRNA), and can be 
mistakenly inserted in place of aminoacyl-tRNA by ribosome and acts as a universal 
protein translation inhibitor. We have constructed a series of puromycin analogs with 
natural and unnatural amino acids side chains in order to systematically test the effects of 
side chain characteristics of amino acid moiety on the activity of puromycin. We then 
measured the activity of each compound in a high dynamic-range IC50 potency assay 
using the rabbit reticulocyte protein synthesis system. Both IC50 values and 
carboxypeptidase Y (CPY)-resistant results lead us to conclude that all of the compounds 
we synthesized both inhibit translation and participate in ribosome-mediated peptide 
bond formation.    
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Introduction 
Puromycin has played an important role in our understanding of the ribosome and 
protein synthesis.  Puromycin is a small-molecule mimic of aminoacyl-tRNA (aa-tRNA), 
and can be mistakenly inserted in place of aminoacyl-tRNA by ribosome and acts as a 
universal protein translation inhibitor (Figure 1).  It enters the ribosomal A site and 
participates in peptide bond formation with the nascent peptidyl chain,1 resulting in 
truncated proteins containing the drug at their C-terminus.  Puromycin and puromycin 
analogs have been extremely useful in exploring the activity of various nucleophiles (-
OH vs. -NH2 vs. -SH) in the ribosome active site.2-5 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structural comparison between Tyrosine-tRNA and puromycin. 
 
Unlike aa-tRNA, puromycin is able to enter the ribosome independently (Figure 2), 
does not induce EF-Tu•GTPase activiy,6 and does not appear to require soluble 
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translation factors for function.7  Puromycin and related analogs thus provide a direct 
means to address ribosome-mediated peptide bond formation even in an intact translation 
extract. 
 
 
 
 
 
 
 
 
Figure 2. D-puromycin incorporated in the peptidyltransferase center of the ribosome. 
 
The protein synthesis machinery can be used to incorporate unnatural amino acids 
into peptides,8-10 proteins,11,12 and molecular libraries.13-18 These studies indicate that the 
ribosome displays a broad ability to utilize residues beyond the 20 naturally occurring 
amino acids.  Chemically misacylated tRNA fragments and tRNAs provide one route to 
probe the stereo- and regiospecificity of isolated ribosomes19-22 and intact translation 
systems.23 This approach has expanded our understanding of the range of residues that 
can be incorporated by the ribosome.24-27 However, entry of both β- and D-amino acids 
has proved challenging.9,11  Analysis of incorporation of these residues would be valuable 
and deepen our understanding of the stereo- and regiochemical constraints of ribosome-
mediated peptide bond formation. 
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Materials and Methods 
General Information.  
 1H and 13C NMR spectra were recorded on a Varian, Inc. UNITY INOVA instrument 
operating at 500 MHz using D2O or DMSO-d6 as the solvent.  1H NMR data are reported 
as follows:  s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet; dd, 
doublet of doublets.  High-resolution mass spectra (FAB) were recorded on a JMS-600H 
double-focusing, high-resolution, magnetic sector mass spectrometer at the Mass 
Spectrometry Laboratory, Division of Chemistry and Chemical Engineering, California 
Institute of Technology.  Column chromatography was carried out on silica gel (40-63 
µm, EM Science).  Analytical HPLC was performed using a Vydac C18 column (5 mm, 
4.5 x 250 mm) with buffer A (5 mM NH4OAc, pH 5.5 with 10% acetonitrile) and buffer 
B (5 mM NH4OAc, pH 5.5 with 90% acetonitrile); a linear gradient of 100% buffer B in 
50 min was used with a flow rate of 1 mL/min.  All reagents were of highest available 
commercial quality and were used without further purification.  Puromycin 
aminonucleoside (3’-amino-3’-deoxy-N, N’-dimethyl-adenosine) (PANS) was purchased 
from Sigma Chemical Co.  FMOC-(4-methoxy-D-phenylalanine) and FMOC-(D-alanine) 
were purchased from Bachem.  FMOC-(4-methyl-L-phenylalanine), FMOC-(L-alanine), 
and FMOC-(L-β-homoalanine) were purchased from Fluka.  FMOC-(4-methyl-D-
phenylalanine) and FMOC-(4-methyl-L-β-phenylalanine) were from Peptech.  Puromycin 
and puromycin analog concentrations were determined with the following extinction  
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coefficients (M-1cm-1) at 260 nm:  L- and D-puromycin (1a and 1b) [ε = 11,790] in H2O; 
L-(4-Me)-Phe-PANS, D-(4-Me)-Phe-PANS, and L-β-(4-Me)-Phe-PANS (2a – 2c) [ε = 
10,500] in H2O; and L-Ala-PANS, D-Ala-PANS, and L-β-Ala-PANS (3a – 3c) [ε = 
11,000] in phosphate buffered saline (pH 7.3). 
Rabbit reticulocyte lysate was purchased from Novagen.  Rabbit globin mRNA 
was obtained from Life Technologies Gibco BRL.  L-Puromycin (1a) was purchased 
from Sigma Chemical Co.  Ras mRNA was prepared by using two DNA primers 
complementary to the 5’- and 3’-ends of the coding region for H-Ras (pProEX HTb 
vector, a kind gift from Dafna Bar-Sagi)1 to amplify the gene using PCR.  mRNA was 
produced by T7 runoff transcription2 of the H-Ras DNA in the presence of RNAsecure 
(Ambion) followed by gel purification via denaturing urea-PAGE and ‘crush and soak’ 
RNA isolation.  L-[35S]methionine (1,175 Ci/mmol) was purchased from NEN Life 
Science Products.  Carboxypeptidase Y was obtained from Pierce.  GF/A glass microfiber 
filters were from Whatman.  Scintillation counting was carried out using a Beckman LS-
6500 liquid scintillation counter. 
 
General Procedure for Preparation of Puromycin Analogs.  
 N, N’-dicyclohexylcarbodiimide (DCC) (0.0539 mmol) was added to a cold (0 
°C) solution of PANS (0.0520 mmol), FMOC-protected amino acid (0.0541 mmol), and 
N-hydroxysuccinimide (NHS) (0.0556 mmol) in dried N,N’-dimethylformamide (DMF) 
(0.900 mL).  The solution was stirred for 30 min in an ice-water bath and then for 25 h at  
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ambient temperature.  N,N’-dicyclohexylurea was filtered and washed (EtOAc, 4 mL), 
and the filtrate was concentrated in vacuo.  For 1b, the residue was resuspended in 
EtOAc, sonicated, and the mixture was filtered and then dried.  The material was purified 
by gradient flash chromatography using CHCl3 → MeOH/CHCl3 (4:96) for 1b or 
MeOH/CHCl3 (7:93) for 2a-2c and 3a-3c.  Homogenous product fractions were dried in 
vacuo to yield the FMOC-protected product.  FMOC-deprotection was carried out in 20% 
(v/v) piperidine in DMF (5mL) with stirring for 30 min at ambient temperature.  The 
solvent was removed in vacuo and the residue was subjected to gradient flash 
chromatography using CHCl3 → MeOH/CHCl3 (8:92) for 1b, 2a, and 2b and 
TEA/MeOH/CHCl3 (2:10:88) for 2c and 3a-3c to afford the titled products.  
Confirmation of purity was assessed using analytical HPLC. 
9-{3’-Deoxy-3’-[(4-methoxy-D-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine (D-puromycin) (1b).3  White solid (31.5 mg, 87.3%):  1H 
(DMSO-d6) δ 1.85 ( br s, 2H), 2.58-2.63 (m, 1H), 2.93 (dd, J = 4.5, 14 Hz, 1H), 3.42 (dd, 
J = 4.5, 8.5 Hz, 2H), 3.51-3.56 (m, 2H), 3.72 (s, 6H), 3.93-3.96 (m, 1H), 4.47-4.51 (m, 
4H), 5.17 (t, J = 5.5 Hz, 1H), 5.97 (d, J = 2.0 Hz, 1H), 6.17 (d, J = 5.0, 1H), 6.85 (d, J = 
9.0 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 8.08 (br s, 1H), 8.24 (s, 1H), 8.45 (s, 1H); 13C 
(DMSO-d6) δ 25.4, 50.6, 56.0, 56.8, 61.7, 73.8, 84.4, 90.2, 114.3, 131.0, 138.7, 150.4, 
152.6, 158.0, 175.5; HRMS (FAB), m/z calculated for C22H30N7O5 (M+H)+ 472.2311, 
found 472.2307. 
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9-{3’-Deoxy-3’-[(4-methyl-L-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [L-(4-Me)-Phe-PANS] (2a).  Pale white solid (18.8 mg, 
80.8%):  1H NMR (DMSO-d6) δ 1.84 (br s, 2H), 2.26 (s, 6H), 2.52-2.57 (m, 1H), 2.94 
(dd, J = 4.5, 14 Hz, 1H), 3.44-3.52 (m, 2H), 3.67-3.70 (m, 2H), 3.92-3.95 (m, 1H), 4.44-
4.50 (m, 4H), 5.14 (t, J = 5.5 Hz, 1H), 5.98 (d, J = 3.0 Hz, 1H), 6.14 (d, J = 4.0 Hz, 1H), 
7.10 (dd, J = 8.0, 18 Hz, 4H), 8.07 (d, J = 5.5 Hz, 1H), 8.24 (s, 1H), 8.45 (s, 1H); 13C 
(DMSO-d6) δ 21.3, 41.2, 50.7, 56.9, 61.7, 73.9, 84.3, 90.2, 120.3, 129.4, 129.8, 135.7, 
136.3, 138.7, 150.4, 152.6, 155.0, 175.5; HRMS (FAB), m/z calculated for C22H30N7O4 
(M+H)+ 456.2362, found 456.2367. 
9-{3’-Deoxy-3’-[(4-methyl-D-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [D-(4-Me)-Phe-PANS] (2b).  Pale white solid (20.7 mg, 
88.8%):  1H NMR (DMSO-d6) δ 1.85 (br s, 2H), 2.26 (s, 6H), 2.61 (dd, J = 8.0, 13 Hz, 
1H) 2.96 (dd, J = 4.5, 14 Hz, 1H), 3.42-3.45 (m, 1H), 3.51-3.56 (m, 1H), 3.71-3.73 (m, 
2H), 3.94-3.96 (m, 1H), 4.40-4.49 (m, 4H), 4.48 (d, J = 12 Hz, 1H), 5.17 (t, J = 5.5 Hz, 
1H), 5.97 (d, J = 2.5 Hz, 1H), 6.19 (br s, 1H), 7.11 (dd, J = 8.0, 16 Hz, 4H), 8.10 (br s, 
1H), 8.23 (s, 1H), 8.45 (s, 1H); 13C (DMSO-d6) δ 21.4, 41.0, 50.6, 56.8, 61.7, 73.8, 84.4, 
90.2, 120.3, 129.4, 129.9, 135.8, 136.1, 138.7, 150.4, 152.6, 155.0, 175.5; HRMS (FAB), 
m/z calculated for C22H30N7O4 (M+H)+ 456.2362, found 456.2360. 
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9-{3’-Deoxy-3’-[(4-methyl-L-β-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [L-β-(4-Me)-Phe-PANS] (2c).  Pale white solid (17.8 mg,  
73.0%):  1H NMR (D20) δ 2.06 (s, 6H), 2.45-2.49 (m, 1H), 2.67 (d, J = 6.5 Hz, 1H), 3.18 
(t, J = 6.0 Hz, 1H), 3.28 (br s, 3H), 3.37-3.39 (m, 1H), 3.49-3.50 (m, 1H), 3.59-3.62 (m, 
1H), 3.80 (dd, J = 2.0, 13 Hz, 1H), 4.08-4.10 (m, 1H), 4.35 (dd, J = 6.0, 8.5 Hz, 1H), 4.46 
(dd, J = 3.0, 5.5 Hz, 1H), 5.94 (d, J = 2.5 Hz, 1H), 7.03 (s, 4H), 8.03 (s, 1H), 8.15 (s, 1H); 
13C NMR (D20) δ 19.1, 26.0, 40.5, 49.8, 50.5, 54.5, 60.8, 73.6, 82.7, 89.7, 111.0, 120.0, 
129.4, 129.6, 134.0, 137.2, 138.0, 148.8, 152.3, 173.6; HRMS (FAB), m/z calculated for 
C23H32N7O4 (M+H)+ 470.2519, found 470.2508. 
9-{3’-Deoxy-3’-[(L-alanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (L-Ala-PANS) (3a).  Pale yellow solid (5.7 mg, 30.2%):  1H 
NMR (D2O) δ 1.41 (d, J = 7.0 Hz, 3H), 3.28 (br s, 6H), 3.63 (dd, J = 3.5, 13 Hz, 1H), 
3.82 (dd, J = 2.5, 13 Hz, 1H), 3.97 (q, J = 7.0 Hz, 1H), 4.17-4.18 (m, 1H), 4.55-4.58 (m, 
2H), 4.62-4.64 (m, 1H), 5.98 (d, J = 3.0 Hz, 1H), 8.03 (s, 1H), 8.17 (s, 1H); 13C NMR 
(D2O) δ 17.3, 39.0, 49.4, 51.0, 60.7, 73.5, 82.7, 89.6, 119.5, 138.0, 148.8, 152.2, 154.6, 
172.4; HRMS (FAB), m/z calculated for C15H24N7O4 (M+H)+ 366.1892, found 366.1889. 
9-{3’-Deoxy-3’-[(D-alanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (D-Ala-PANS) (3b).  Pale yellow solid (8.6 mg, 45.4%):  1H 
NMR (D20) δ 1.43 (d, J = 7.5 Hz, 3H), 3.28 (br s, 6H), 3.65 (dd, J = 4.0, 13 Hz, 1H), 3.83 
(dd, J = 2.5, 13 Hz, 1H), 4.02 (q, J = 7.5 Hz, 1H), 4.14-4.17 (m, 1H), 4.55-4.58 (m, 2H), 
4.64-4.66 (m, 1H), 5.98 (d, J = 3.0 Hz, 1H), 8.04 (s, 1H), 8.17 (s, 1H); 13C NMR (D20)  
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δ 17.0, 39.0, 49.3, 50.9, 60.8, 73.3, 82.8, 89.6, 106.0, 119.6, 138.1, 152.3, 154.8, 172.0; 
HRMS (FAB), m/z calculated for C15H24N7O4 (M+H)+ 366.1892, found 366.1898. 
9-{3’-Deoxy-3’-[(L-β-homoalanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (L-β-Ala-PANS) (3c).  Pale yellow solid (4.6 mg, 25.6%):  1H 
NMR (D20) δ 1.16 (d, J = 6.5 Hz, 3H), 1.74 (s, 1H), 2.52 (d, J = 3.5 Hz, 2H), 3.24 (br s, 
6H), 3.52-3.61 (m, 2H), 3.78 (d, J = 13 Hz, 1H), 4.11 (d, J = 5.5 Hz, 1H), 4.62-4.64 (m, 
2H), 5.93 (s, 1H), 7.99 (s, 1H), 8.13 (s, 1H); 13C NMR (D20) δ 18.2, 39.0, 39.5, 45.0, 
50.7, 60.7, 73.5, 82.7, 89.6, 119.5, 138.0, 148.8, 152.2, 172.7; HRMS (FAB), m/z 
calculated for C16H26N7O4 (M+H)+ 380.2049, found 380.2054. 
 
IC50 Determination.   
Translation reactions containing [35S]Met were made up in batch on ice and added 
in aliquots to microcentrifuge tubes containing an appropriate amount puromycin or 
puromycin analog dried in vacuo.  Typically, a 20 µl translation mixture consisted of 0.8 
µL of 2.5 M KCl, 0.4 µL of 25 mM MgOAc, 1.6 µL of 12.5X Translation Mixture 
without methionine (25 mM dithiothreitol (DTT), 250 mM HEPES (pH 7.6), 100 mM 
creatine phosphate, and 312.5 µM of 19 amino acids, except methionine), 3.6 µL of 
nuclease-free water, 0.6 µL (6.1 µCi) of [35S]Met (1175 Ci/mmol), 8 µL of Red Nova® 
nuclease-treated lysate, and 5 µL of 0.05 µg/µL globin mRNA.  Inhibitor, lysate 
preparation  (include all components except template), and globin mRNA were mixed 
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simultaneously and incubated at 30 ºC for 60 min.  Then 2 µL of each reaction was 
combined with 8 µL of tricine loading buffer (80 mM Tris-Cl (pH 6.8), 200 mM DTT, 
24% (v/v) glycerol, 8% sodium dodecyl sulfate (SDS), and 0.02 % (w/v) Coomassie blue 
G-250), heated to 90 ºC for 5 min, and applied entirely to a 4% stacking portion of a 16% 
tricine SDS-polyacrylamide gel containing 20% (v/v) glycerol4 (30 mA for 1.5h).  Gels 
were fixed in 10% acetic acid (v/v) and 50% (v/v) methanol, dried, exposed overnight on 
a PhosphorImager screen, and analyzed using a Storm PhosphorImager (Molecular 
Dynamics).  Analysis in Figure S1 was carried out as described above except 6 µL of 
each reaction and 24 µL of tricine loading buffer were loaded (1.5-fold increase in 
stacking and resolving portion of gel; 30mA for 7 h). 
 
Carboxypeptidase Assay.   
 
Translation reactions were prepared as described for IC50 determination except reactions 
(50 µL) contained 2 µL of 2.5 M KOAc, 1 µL of 25 mM MgOAc, 4 µL of 12.5X 
Translation Mixture without methionine (25 mM dithiothreitol (DTT), 250 mM HEPES 
(pH 7.6), 100 mM creatine phosphate, and 312.5 µM of 19 amino acids, except 
methionine), 16 µL (163 µCi) of [35S]Met (1175 Ci/mmol), 20 µL of Red Nova® 
nuclease-treated lysate, and 6.96 µL of 230 µg/mL Ras mRNA.3  Inhibitor, lysate 
components, and Ras mRNA were mixed simultaneously and incubated at 30 ºC for 60 
min.  Then 2 µL of reaction was combined with 150 µL of 0.1 M sodium acetate (pH 5.0)  
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and 17 µL carboxypeptidase Y (CPY) (1 mg/mL in 0.05 M sodium citrate (pH 5.3) 
Pierce), and incubated at 37 ºC for 18 h.  After incubation, reactions were mixed with 100 
µL of 1 N NaOH/2% H2O2 (hydrolyzes charged tRNAs and removes the red color that 
may quench scintillation counting) and incubated at 37 ºC for 10 min to hydrolyze the 
charged tRNAs.  Then 0.9 mL of 25% trichloroacetic acid (TCA)/2% casamino acids was 
added to the samples, vortexed, and put on ice for 10 min.  The samples were filtered on 
GF/A filters (pre-soaked in 5% TCA), washed 3 times with 3-mL portions of cold 5% 
TCA, and scintillation counted to determine the amount of [35S]Met-Ras.  For the no 
CPY-treated samples, [35S]Met-Ras (2 µL of reaction) was TCA precipitated without 
CPY treatment as described above.   
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Results 
Here, we have used a series of synthetic puromycin analogs with a variety of α-amino 
acid moieties in both L- and D-configurations, and β-amino acids, to measure their 
activity in an intact eukaryotic translation system.  We have synthesized a series of 
puromycin derivatives (Figure 3) that differ in the 1) amino acid moiety, 2) amino acid 
stereochemistry, and 3) number of carbon units in the amino acid backbone. The 
synthesis route of these compounds is outlined in Scheme 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of puromycin analogs (Lys- derivative is used here as an example) 
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Figure 3A.  Puromycin analogs with L- and D- α-amino acid side chains. 
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Figure 3B.  Puromycin analogs with L-β- amino acid sidechains. 
 
 
 
We then measured the activity of each compound in a high dynamic-range IC50 
potency assay using the rabbit reticulocyte protein synthesis system.7  The naturally 
occurring compound, L-puromycin (1a), inhibits globin mRNA translation with an IC50 
of 1.8 µM (Table 1). Surprisingly, D-puromycin (1b) also inhibited translation giving an 
IC50 of 280 µM, a difference of 150-fold (Figure 4). 
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Figure 4.  IC50 determination for puromycin. (A) Tricine-SDS-PAGE analysis of 
[35S]Met-globin translation reactions in the presence of L-puromycin (1a) and D-
puromycin (1b):  Lane 1, no template; lane 2, globin alone; lanes 3-10, concentrations 
from 50 nM to 10 mM for 1a and from 100 nM to 20 mM for 1b.  (B) Percent globin 
translation relative to the no drug control for L-puromycin (1a) and D-puromycin (1b).  
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We reasoned that stereoselectivity should be a function of the side chain size and 
geometry.  To test this, we constructed compounds where the puromycin side chain was 
altered to bear either a bulky aromatic side chain (L- and D-4-methyl-phenylalanine; 2a 
and 2b), aliphatic side chains of different length (L- and D-alanine, 3a and 3b; L- and D-
methionine, 4a and 4b; L- and D-norleucine, 5a and 5b; L- and D-leucine, 6a and 6b; L- 
and D-valine, 7a and 7b), a charged side chains  (L- and D-lysine, 8a and 8b), or a polar 
side chains  (L- and D-Biocytin, 9a and 9b). 
 
Table 1.  IC50 values for puromycin analogs. 
 
 Puromycin Analogs IC50 (µM) 
L- (a)           D- (b) 
 
D/L 
 
1 Puromycin 1.8 280 156 
 
2 (4-Me)-Phe-PANS 1.0 2400 2400 
 
3 Ala-PANS 730 1900 2.6 
 
4 Met-PANS 15 765 51 
 
5 Nle-PANS 61 937 15 
 
6 Leu-PANS 105 776 7.4 
 
7 Val-PANS 3500 5300 1.5 
 
8 Lys-PANS 289 347 1.2 
 
9 Biocytin-PANS 2900 2900 1.0 
 
10 β-(4-Me)-Phe-PANS 600 - - 
 
11 β-Ala-PANS 1700 - - 
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Compound 2a inhibits translation better than puromycin itself (IC50 = 1.0 µM) and is 
the most potent compound we constructed.  The D-amino acid variant (2b) shows 
significantly reduced activity (IC50 = 2400 µM) with ~9-fold reduced activity compared 
to D-puromycin (1b), and is 2400-fold less potent than the L-isomer. 
Compared to the natural occurring L-puromycin (1.8 µM), the other analogs we 
constructed, including Methionine (Met), Leucine (Leu), NorLeucine (Nle), Lysine (Lys), 
Biocytin, and Valine (Val), Alanine (Ala), are all less potent as inhibitor of protein 
synthesis (Table 1), but they show some interesting trend. For example, the IC50 values 
for L-Lys and D-Lys analogs are very similar, 289 µM and 347 µM, respectively. This 
shows that the ribosome perhaps does not discriminate L- and D-configurations for 
charged amino acid analogs. To be consistent with this observation, the puromycin 
analogs with biocytin side chain (biotinylated lysine) also have the same IC50 (2900 µM) 
between the L- and D-configuration, though much less potent. 
The IC50 values for the puromycin analog with unnatural amino acid L-Nle and D-Nle 
are 61 µM and 937 µM, respectively. The Nle has the same aliphatic side chain as Lys 
but lacks the terminal amino group therefore lacks the positive charge. In contrast to Lys 
derivatives, L-Nle is 15-fold more potent than its D- counterpart. This allows us to 
conclude that the more hydrophobic the amino acid moiety, the more different is the 
potency of the D- and L- puromycin analog, consistent with our previous observation that 
larger hydrophobic aromatic side chain is a key element of ribosome discrimination. 
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In line with this observation, the Leu analogs have IC50 values of 105 µM and 776 
µM for L- and D-configuration, a 7-fold difference (Figure 5). These are very similar to 
the Nle analogs because Leu and Nle have similar aliphatic side chains. For Met, L-
configuration (15 µM) is about 51-fold different than the D-configuration (765 µM). On 
the contrary, Val analogs are much less potent, having IC50 values of 3500 µM and 5300 
µM, with little discrimination, similar to the case of Ala. The alanine analogs show only a 
3-fold selectivity for the L- versus D- isomers (3a vs. 3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  IC50 comparison for L- and D- puromycin.  
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We then next examined puromycin derivatives bearing β-amino acids.  β-amino acids 
have been previously incorporated at low levels using nonsense suppression 
techniques.10,11 In our experiments, both L-β-(4-Me)-Phe-PANS (10) and L-β-Ala-PANS 
(11) gave measurable inhibition constants (IC50 = 600 and 1700 µM, respectively) (Table 
1). 
Finally, we wished to confirm that our puromycin analogs participated in peptide 
bond formation within the ribosome.  Incorporation of puromycin blocks the C-terminus, 
rendering the protein carboxypeptidase resistant.1 Previous work in our laboratory 
indicated that puromycin incorporation  is measureable when the analog concentration is 
near the IC50.7  Protein synthesis performed in the presence of our puromycin derivatives 
resulted in a 12- to 16-fold increase in carboxypeptidase Y (CPY)-resistant protein 
compared with the no puromycin, Ras only control (Figures 6A & B).  The production of 
truncated protein fragments in the presence of each puromycin derivative, previously 
shown to result from puromycin attachment to globin,7 along with the CPY-resistance 
results lead us to conclude that all of the compounds we synthesized both inhibit 
translation and participate in ribosome-mediated peptide bond formation.    
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Figure 6.  Carboxypeptidase Y (CPY) analysis of protein-puromycin products.11  TCA 
precipitation of [35S]Met-protein (Ras) from translation reactions after CPY treatment 
containing (A) Ras only, L-puromycin (1a) at 2 µM and D-puromycin (1b) at 500 µM 
and (B) Ras only, L-(4-Me)-Phe-PANS (2a) at 1 µM, D-(4-Me)-Phe-PANS (2b) at 1500 
µM, and L-β-(4-Me)-Phe-PANS (2c) at 1000 µM.  Data represent the mean ± standard 
error for at least three independent experiments. 
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Discussions 
We vision that stereoselectivity should be a function of the side chain size and 
geometry.  In order to systematically test the effects of size chain characteristics of amino 
acid moiety on the activity of puromycin, we have constructed a series of puromycin 
analogs with natural and unnatural amino acids side chains. These compounds include 4-
methyl-Phenylalanine, Alanine(Ala), Methionine (Met), Leucine (Leu), NorLeucine 
(Nle), Lysine (Lys), Biocytin, and Valine (Val), in addition to naturally occurring 
puromycin, in both L- and D-configurations. They have either aromatic, aliphatic 
hydrophobic side chains of different length, or charged/polar side chains. This allows us 
to specifically probe different type of interactions between these analogs with the 
ribosome. We have used the same high dynamics IC50 assay to measure the activities of 
these puromycin analogs in inhibition of globin translation. 
These observations argue that ribosomal stereoselectivity falls over a broad range 
and is primarily dictated by the size and geometry of the pendant side chain.  Within the 
L-amino acid series (1a, 2a, and 3a), marked variation is also seen based solely on side 
chain identity.  Larger, hydrophobic side chains provide improved function. In the L-
amino acid series, 4-methylphenylalanine and naturally occurring puromycin are the best, 
followed by long aliphatic amino acids (Met, Nle, Leu). This is consistent with previous 
observations.4,5  In the D-amino acid series, the 4-O-methyltyrosine derivative (1b) 
functions the best overall, and shows even better activity than the natural L-Ala and L-
Val variants. 
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Overall, an aromatic side chain provides the highest stereospecificity by ribosome 
between L- and D-configuration, followed by long hydrophobic aliphatic side chains. 
Charged and polar side chains provide little discrimination. 
We proposed that steric hindrance is the main reason that L-puromycin analogs 
are in general more potent than D-analogs (Figure 7), and our observation that aromatic 
and hydrophobic amino acid side chains exhibit higher discrimination than either charged 
or smaller side chains is consistent with this hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Model for D-puromycin (red) placement in the large 50S ribosome CCdA-p-L-
puromycin (blue) complex. There is some potential hydrogen bond interactions of Met 
side chain with A2486. 
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The structural basis for stereoselectivity in rabbit ribosomes cannot be addressed 
presently, as there are no high-resolution structures available.  However, modeling D-
puromycin (1b) into the active site of the Haloarcula marismortui 50S subunit28 is 
consistent with the idea that steric effects play a role in chiral discrimination.  In the 
atomic resolution structure, U2620 (U2585 E. coli) is the closest nucleotide to the D-side 
chain. Also, while many of the ribosome active site nucleotides are highly conserved, the 
fact that critical residues can be mutated,29 implies that construction of ribosomes with 
altered stereo- and regiospecificity may be possible. In the case of Met, there could 
potentially be hydrogen bonding interactions with the sulphur atom from the ribosome 
nucleotide for the L-derivative and this is consistent with the fact that there is about 51 
fold difference between L- and D- Met-PANS. 
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Conclusions 
Our work demonstrates that L-, D-, and β-amino acids can participate in ribosome-
mediated peptide bond formation when constructed as analogs of puromycin. Our 
approach allows us to examine the activity of the ribosome directly in a physiologically 
complete protein-synthesizing system. Measurements using intact systems are critical as 
these can produce very different results from reconstituted or purified systems that are 
incapable of synthesizing proteins.30,31  Our results provide one metric of the chiral and 
regiospecificity of mammalian ribosomes.  We are hopeful that this data along with other 
information, such as the ability to optimize tRNA affinity for elongation factor Tu (EF-
Tu)32,33(EF1A in eukaryotes), will facilitate the incorporation of desirable but recalcitrant 
residues into peptides and proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
  
91
 
References 
 
 1. Nathans, D. Puromycin Inhibition of Protein Synthesis - Incorporation of 
Puromycin into Peptide Chains. Proc Natl Acad Sci U S A 51, 585-& (1964). 
2. Fahnesto.S, Neumann, H., Shashoua, V. & Rich, A. Ribosome-Catalyzed Ester 
Formation. Biochemistry 9, 2477-& (1970). 
3. Gooch, J. & Hawtrey, A. O. Synthesis of Thiol-Containing Analogues of 
Puromycin and a Study of Their Interaction with N-Acetylphenylalanyl-Transfer 
Ribonucleic-Acid on Ribosomes to Form Thioesters. Biochemical Journal 149, 
209-220 (1975). 
4. Nathans, D. & Neidle, A. Structural Requirements for Puromycin Inhibition of 
Protein Synthesis. Nature 197, 1076-& (1963). 
5. Harris, R. J., Hanlon, J. E. & Symons, R. H. Peptide Bond Formation on 
Ribosome - Structural Requirements for Inhibition of Protein Synthesis and of 
Release of Peptides from Peptidyltransferrna on Bacterial and Mammalian 
Ribosomes by Aminoacyl and Nucleotidyl Analogues of Puromycin. Biochimica 
Et Biophysica Acta 240, 244-& (1971). 
6. Campuzano, S. & Modolell, J. Hydrolysis of Gtp on Elongation-Factor 
Tu.Ribosome Complexes Promoted by 2'(3')-O-L-Phenylalanyladenosine. Proc 
Natl Acad Sci U S A 77, 905-909 (1980). 
  
92
7. Starck, S. R. & Roberts, R. W. Puromycin oligonucleotides reveal steric 
restrictions for ribosome entry and multiple modes of translation inhibition. RNA 
8, 890-903 (2002). 
8. Heckler, T. G., Zama, Y., Naka, T. & Hecht, S. M. Dipeptide Formation with 
Misacylated Transfer Rna-Phes. Journal of Biological Chemistry 258, 4492-4495 
(1983). 
9. Bain, J. D., Glabe, C. G., Dix, T. A., Chamberlin, A. R. & Diala, E. S. 
Biosynthetic Site-Specific Incorporation of a Non-Natural Amino-Acid into a 
Polypeptide. J Am Chem Soc 111, 8013-8014 (1989). 
10. Bain, J. D., Wacker, D. A., Kuo, E. E. & Chamberlin, A. R. Site-Specific 
Incorporation of Nonnatural Residues into Peptides - Effect of Residue Structure 
on Suppression and Translation Efficiencies. Tetrahedron 47, 2389-2400 (1991). 
11. Noren, C. J., Anthony-Cahill, S. J., Griffith, M. C. & Schultz, P. G. A general 
method for site-specific incorporation of unnatural amino acids into proteins. 
Science 244, 182-8 (1989). 
12. Nowak, M. W. et al. Nicotinic Receptor-Binding Site Probed with Unnatural 
Amino-Acid-Incorporation in Intact-Cells. Science 268, 439-442 (1995). 
13. Li, S., Millward, S. & Roberts, R. In vitro selection of mRNA display libraries 
containing an unnatural amino Acid. J Am Chem Soc 124, 9972-3 (2002). 
14. Takahashi, T. T., Austin, R. J. & Roberts, R. W. mRNA display: ligand discovery, 
interaction analysis and beyond. Trends Biochem Sci 28, 159-65 (2003). 
15. Ellman, J. A., Mendel, D. & Schultz, P. G. Site-Specific Incorporation of Novel 
Backbone Structures into Proteins. Science 255, 197-200 (1992). 
  
93
16. Ellman, J., Mendel, D., Anthony-Cahill, S., Noren, C. J. & Schultz, P. G. 
Biosynthetic method for introducing unnatural amino acids site-specifically into 
proteins. Methods Enzymol 202, 301-36 (1991). 
17. van Hest, J. C. M. & Tirrell, D. A. Protein-based materials, toward a new level of 
structural control. Chem Commun, 1897-1904 (2001). 
18. Cornish, V. W., Mendel, D. & Schultz, P. G. Probing Protein-Structure and 
Function with an Expanded Genetic-Code. Ange Chem-Int Ed 34, 621-633 
(1995). 
19. Yamane, T., Miller, D. L. & Hopfield, J. J. Discrimination between D-Tyrosyl 
and L-Tyrosyl Transfer Ribonucleic-Acids in Peptide-Chain Elongation. 
Biochemistry 20, 7059-7064 (1981). 
20. Chladek, S. & Sprinzl, M. The 3'-End of Transfer-Rna and Its Role in Protein-
Biosynthesis. Ange Chem-Int Ed 24, 371-391 (1985). 
21. Heckler, T. G., Roesser, J. R., Xu, C., Chang, P. I. & Hecht, S. M. Ribosomal-
Binding and Dipeptide Formation by Misacylated Transfer Rnaphes. 
Biochemistry 27, 7254-7262 (1988). 
22. Roesser, J. R., Xu, C., Payne, R. C., Surratt, C. K. & Hecht, S. M. Preparation of 
Misacylated Aminoacyl-Transfer Rna Phes Useful as Probes of the Ribosomal 
Acceptor Site. Biochemistry 28, 5185-5195 (1989). 
23. Mendel, D., Ellman, J. & Schultz, P. G. Protein-Biosynthesis with 
Conformationally Restricted Amino-Acids. J Am Chem Soc 115, 4359-4360 
(1993). 
  
94
24. Killian, J. A., Van Cleve, M. D., Shayo, Y. F. & Hecht, S. M. Ribosome-mediated 
incorporation of hydrazinophenylalanine into modified peptide and protein 
analogues. J Am Chem Soc 120, 3032-3042 (1998). 
25. Koh, J. T., Cornish, V. W. & Schultz, P. G. An experimental approach to 
evaluating the role of backbone interactions in proteins using unnatural amino 
acid mutagenesis. Biochemistry 36, 11314-11322 (1997). 
26. Eisenhauer, B. M. & Hecht, S. M. Site-specific incorporation of (aminooxy)acetic 
acid into proteins. Biochemistry 41, 11472-11478 (2002). 
27. England, P. M., Zhang, Y. N., Dougherty, D. A. & Lester, H. A. Backbone 
mutations in transmembrane domains of a ligand-gated ion channel: Implications 
for the mechanism of gating. Cell 96, 89-98 (1999). 
28. Nissen, P., Hansen, J., Ban, N., Moore, P. B. & Steitz, T. A. The structural basis 
of ribosome activity in peptide bond synthesis. Science 289, 920-930 (2000). 
29. Polacek, N., Gaynor, M., Yassin, A. & Mankin, A. S. Ribosomal peptidyl 
transferase can withstand mutations at the putative catalytic nucleotide. Nature 
411, 498-501 (2001). 
30. Bhuta, P., Kumar, G. & Chladek, S. Aminoacyl Derivatives of Nucleosides, 
Nucleotides and Polynucleotides .36. The Peptidyltransferase Center of 
Escherichia-Coli Ribosomes - Binding-Sites for the Cytidine 3'-Phosphate 
Residues of the Aminoacyl-Trna 3'-Terminus and the Interrelationships between 
the Acceptor and Donor Sites. Biochimica Et Biophysica Acta 696, 208-211 
(1982). 
  
95
31. Krayevsky, A. A. & Kukhanova, M. K. The peptidyltransferase center of 
ribosomes. Prog Nucleic Acid Res Mol Biol 23, 1-51 (1979). 
32. LaRiviere, F. J., Wolfson, A. D. & Uhlenbeck, O. C. Uniform binding of 
aminoacyl-tRNAs to elongation factor Tu by thermodynamic compensation. 
Science 294, 165-168 (2001). 
33. Asahara, H. & Uhlenbeck, O. C. The tRNA specificity of Thermus thermophilus 
EF-Tu. Proc Natl Acad Sci U S A 99, 3499-504 (2002). 
 
  
96
 
Chapter 4 
 Total Synthesis of Hydroxymethylacylfulvene 
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Abstract 
Hydroxymethylacylfulvene (1) (HMAF, also MGI 114) is a promising antitumor 
compound derived from the sesquiterpene illudin S (2).  It is less cytotoxic than illudin S 
to normal cells and exhibits much greater selectivity in toxicity to malignant cells.  A 
simple synthetic method is demonstrated to rapidly construct the skeleton of HMAF and 
its analogs starting from 2-(3-methoxyphenyl)ethanol. In particular this synthesis opens 
the door to enantioselective aromatic oxidation chemistry. 
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Introduction 
Despite massive efforts put forward during the 20th century, human cancers 
continue to devastate the lives of millions of people worldwide.  It has been estimated 
that over 100,000 Americans are diagnosed with cancer per year.  The development of an 
antitumor drug that is highly efficient and less toxic to normal cells is needed.  
Hydroxymethylacylfulvene 1 is derived from the sesquiterpene illudin S by treatment 
with dilute sulfuric acid and excess paraformaldehyde.  Illudin S was first isolated from 
the basidiomycete Omphalotus illudens.  During the past 10 years, extensive preclinical 
studies on HMAF and related fulvenes have been conducted, leading to phase I human 
clinical trials which began in December 1995.  Phase II clinical trials targeting several 
solid tumor types are now in progress under the sponsorship of MGI Pharma and the 
National Cancer Institute.1,2 
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It is well known that many antitumor natural products behave as alkylating agents 
(Scheme 1).  Among them are illudin compounds which react preferentially with thiols, 
and their cytotoxicity is attributed to the ability to react with vital thiol enzymes.  Thiols 
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react readily at room temperature, adding to the α,β-unsaturated carbonyl and giving a 
cyclohexadiene intermediate which rapidly undergoes opening of the cyclopropane and 
loss of the tertiary hydroxyl. Reaction with thiols, e.g., methylthioglycolate, cysteine and 
glutathione is pH-dependent, with the optimum pH being 5.6-6.1. Not surprisingly, 
toxicity can be modulated by varying glutathione levels in cells. A third generation 
analog hydroxymethylacylfulvene (HMAF) caused complete tumor regression in all 
animals at the maximum tolerated dose of 10 mg/kg (iv) three times per week for 3 
weeks. This resulted in increased life span of more than 150%.   HMAF has also been 
found to exhibit outstanding activity against breast, colon, and skin cancer cell lines 
derived from human tumors.1,3-9 
Scheme 1. Studies on the mechanism of action of illudins. 
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Biologically active natural products will have a profound effect on the field of 
medicine in the 21st century.  However, these molecules are commonly isolated in small 
quantities and, therefore, cannot be subjected to advanced biological testing whereby the 
mechanism by which they act can be understood.  Chemical synthesis can produce these 
compounds in the mass quantities necessary for intensive research and therapy. 
 
Retrosynthesis 
 
 
Several syntheses of structurally related compounds have appeared in the 
chemical literatures,10-13 but these syntheses are not suitable for large scale production. A 
retrosynthetic analysis of the total synthesis of Hydroxymethylacylfulvene 1 (HMAF, 
also MGI 114) is illustrated in Scheme 2. Starting from 2-(3-methoxyphenyl)ethanol, our 
strategy should lead to an efficient and versatile synthesis of HMAF and provide access 
to several derivatives of these products in sufficient amounts for further biological 
testing. 
The key features of this synthesis are: (1)Nazarov reaction to form bicyclic 
system (6);14 (2) Enantioselective aromatic oxidation chemistry to install the free hydroxy 
at the chiral center of intermediates (11); (3) Tandem oxidation/cyclopropanation at the 
final stage to afford HMAF efficiently. 
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Scheme 2.  Retrosynthesis of  Hydroxymethylacylfulvene 
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Results and Discussions 
 
 
Starting from (3-methoxy)-2-phenylethanol, compound (3) was synthesized as 
described in the literature.15 The two methyl groups were introduced to the aromatic ring 
by Friedel-Crafts alkylation, followed by LAH or Li/NH3 reduction (Scheme 3). 
 
Scheme 3.  Preparation of the Aromatic Subunit of HMAF.7 
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After benzyl protection of the hydroxyl group in 3-methoxy-2,6-dimethyl 
phenylethanol (3), selective α-bromization was achieved using NBS and silica gel 
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condition. Allylic alcohol (4) was formed by adding t-BuLi and methacrolein. Swern or 
Dess Martin oxidation gave α,β-unsaturated ketone (5) which underwent Nazarov 
reaction to form bicyclic system (6)(Scheme 4). 
 
Scheme 4. Advancing the Aromatic Subunit---Nazarov Reaction 
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The free hydroxyl group of the compound (6) was protected by a silyl group. 
Ketone-alcohol-alkene transformation was achieved by reduction using NaBH4 followed 
by treatment with Burgess’ reagent, or MsCl and Et3N. Phenol (10) was obtained by 
demethylation using BBr3. Free hydroxy at the chiral center of intermediate (11) was 
designed to be installed by enantioselective aromatic oxidation chemistry, using 
Pb(OAc)4 and chiral ligand followed by deacetylation. Instead of screening chiral ligand, 
enzymatic deacetylation will be a good way to achieve enantioselectivity (Scheme 5).  
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Scheme 5. Advancing the aromatic Subunit---Enantioselective aromatic oxidation 
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Final stage manipulation involves screening different base to achieve tandem 
oxidation/cyclopropanation to give known intermediate acylfulvene (12) which 
undergoes an ene reaction with formaldehyde to afford HMAF (1) (Scheme 6).  
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Scheme 6. Tandem oxidation/cyclopropanation 
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Conclusions 
 
This research demonstrated a facile, efficient, and inexpensive synthesis for 
HMAF. In addition, a variety of acylfulvene analogues and their precursors will be 
synthesized and subsequently tested for biological activity. Although the HMAF and 
related molecules are known to have biological activity, the mechanisms by which they 
act remain to be further understood. The development of an efficient total synthesis of 
HMAF and its analogues would allow for the production of large quantities of each and 
thus render advanced biological testing of these molecules possible. The results of these 
experiments could establish precisely how these molecules function. Once the key 
molecular interactions are known, it should be possible to design molecules that have 
improved biological activity, bringing the world closer to uncovering the cure for cancer. 
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